



UNIVERSITI PUTRA MALAYSIA

***EFFECT OF NIGELLA SATIVA ON SELECTED MENOPAUSAL
PARAMETERS IN OVARIECTOMIZED RATS***

SAADAT PARHIZKAR

FPSK(p) 2009 13

**EFFECT OF *NIGELLA SATIVA* ON SELECTED
MENOPAUSAL PARAMETERS IN
OVARIECTOMIZED RATS**

SAADAT PARHIZKAR

**DOCTOR OF PHILOSOPHY
UNIVERSITI PUTRA MALAYSIA**

2009

**EFFECT OF *NIGELLA SATIVA* ON
SELECTED MENOPAUSAL PARAMETERS
IN OVARIECTOMIZED RATS**



SAADAT PARHIZKAR

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

October 2009

DEDICATIONS

Specially dedicated to,

My beloved husband Mr. Mohammad Reza Nazari and my dear sons Reza, Pooya and Parsa for their invaluable support, love, patience and intellectual stimulation making my ambition and dreams come true.

And also dedicated to,

All people who were involved in my learning from the first step until present.

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

**EFFECT OF *NIGELLA SATIVA* ON
SELECTED MENOPAUSAL PARAMETERS
IN OVARIECTOMIZED RATS**

By

SAADAT PARHIZKAR

October 2009

Chairman: Associate Professor Dr. Latiffah A. Latiff, M.D (UKM)

M. Med (PH) (NUS),

Faculty of Medicine and Health Sciences, UPM

and Institute of Biosciences, UPM

Menopause is the condition when regular menstrual periods cease and may be accompanied by psychological and physical symptoms. This is due to ovarian failure and estrogen deficiency which will influence the quality of life. Hormone replacement therapy (HRT) is being used to relieve postmenopausal symptoms thereby improving the quality of life. Prolonged exposure to HRT, however, gives side effects. As such, Complementary and Alternative Medications (CAMs) is being used as an alternative to HRT. *Nigella sativa* (black seed) is used to treat various illnesses and improve health status. Its application in menopausal women however has never been scientifically evaluated.

Three experiments were conducted to investigate the effects of *Nigella sativa* (NS) in ovariectomized (OVX) rats (menopause-induced animal model). The first experiment was to determine the effect of *Nigella sativa* seeds on selected menopausal parameters (estrogen levels, uterine histological changes, vaginal epithelial cell cornification) and metabolic status (lipid profile, body weight and blood glucose level) of ovariectomized rats. Forty OVX rats were divided equally into 5 groups and supplemented for 21 days to one of the following treatments: conjugated equine estrogen (CEE, 0.2mg/kg), distilled water, *Nigella sativa*: low, medium and high doses (300, 600 and 1200 mg/kg). The second experiment was conducted to determine the effects of *Nigella sativa* extracts obtained by different methods of extraction on similar parameters as in experiment one with the exception of uterine histological study. Five groups of eight OVX rats each received of 300 mg/kg of different extracts of *Nigella sativa* (Supercritical Fluid Extraction (SFE), methanol and hexane extracts) or CEE (0.2mg/kg) or olive oil (1ml/day) for 21 days. The third experiment (consisted of two steps) was to determine the fatty acid composition of *Nigella sativa* and to investigate the effects of some of its ingredients on similar parameters as in experiment two. In step 1 of this experiment, various extracts of *Nigella sativa* were analyzed for their fatty acid composition. In step 2, three different chemical components of *Nigella sativa* (linoleic acid, 50 mg/kg; gamma linolenic acid, 10mg/kg; thymoquinone, 15mg/kg) were given to OVX rats. While CEE (0.2mg/kg) and olive oil (1ml/day) were supplemented to the control groups.

The results of the first experiment showed that CEE or *Nigella sativa* supplementation increased ($p < 0.05$) uterine weight as compared to the controls ($290-500 \pm 0.01$ vs

190±0.02 mg for NS and CEE vs control). These supplementations also induced histological changes in the uteri ($p < 0.05$) similar to estrogen induced effect (Endometrial thickness: from 281±39 to 365±123 vs 251±107 μm for NS and CEE vs control). In addition, low dose of *Nigella sativa* supplementation was more effective in inducing the estrogenic-like effects as compared to medium and high doses. The second experiment showed that all extracts of *Nigella sativa* produced estrogen-like effects as compared to the control and the methanolic extract was the most effective (cornification of vaginal epithelial cell percentage 47.62%, 32.87%, 32.46% for methanol, hexane and SFE respectively vs 62% and 00% for positive and negative control respectively). In the third experiment, only linoleic acid showed significant ($p < 0.05$) estrogen-like activities (cornification of vaginal cell percentage 37.92%, 9.50%, 14.62%, 62% for LA, GLA, TQ and CEE respectively vs 00% for control).

In this study, *Nigella sativa* showed estrogen-like effects on the physical, histological and biochemical parameters of OVX rats, thereby indicating the probable beneficial role for the treatment of postmenopausal symptoms. In conclusion, this study provides novel evidence in support of continuing action of the traditional use of *Nigella sativa* in menopausal women. The study also suggests the possibility of using *Nigella sativa* as an alternative to HRT for post menopause in human as indicated in animal model.

Future studies are needed to elucidate the principles, mechanism and active ingredients of *Nigella sativa* on the mammalian reproductive systems.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**KESAN *NIGELLA SATIVA* KE TERHADAP
TIKUSYANG TELAH DIAPUH MENOPOS DARI
PARAMETER-PARAMETER TERTENTU**

Oleh

SAADAT PARHIZKAR

Oktober 2009

Pengerusi: Profesor Madya Dr. Latiffah A. Latiff

Fakulti Perubatan dan Sains Kesihatan, UPM

dan Institut Biosains, UPM

Menopos atau putus haid adalah keadaan di mana wanita berhenti dari mengalami haid, dan keadaan ini boleh diiringi oleh gejala psikologikal dan fizikal. Ini adalah disebabkan oleh kegagalan ovari dan penurunan pengeluaran estrogen yang sering menyebabkan berlakunya perubahan kepada kualiti hidup semasa. Terapi penggantian hormon (HRT) telah digunakan untuk mengurangkan gejala lepas menopos serta meningkatkan kesihatan wanita dan kualiti hidup mereka. Pendedahan berlanjutan kepada HRT walau bagaimanapun boleh memberi kesan yang negatif. Oleh yang demikian, perubahan komplementari pernah digunakan selain dari HRT. *Nigella sativa* (jintan hitam) telah digunakan untuk rawatan bagi pelbagai penyakit dan untuk mampu meningkatkan taraf kesihatan umum. Penggunaannya dalam wanita menopos walaubagaimanapun belum diuji secara saintifik.

Tiga ujian telah dijalankan untuk mengkaji kesan *Nigella sativa* pada haiwan menopause. Kajian pertama ialah untuk menentukan kesan pengambilan *Nigella sativa* dalam pelbagai dos terhadap ciri-ciri menopause terpilih dan status metabolik pada tikus-tikus. Sebanyak empat-puluh ekor tikus yang dibuang ovari (ovariectomized, OVX) dan parameter di bahagikan kepada 5 kumpulan (8 ekor tikus setiap kumpulan) dan diberi suplemen sama ada *Conjugated Equine estrogen* (CEE 0.2mg/kilogram) atau sukatan berbeza serbuk bijirin hitam *Nigella sativa* iaitu. dos rendah (300mg/kilogram), sederhana (600mg/kilogram) dan tinggi (1200mg/kilogram). Kajian kedua pula adalah bagi menentukan kesan-kesan pengambilan ekstrak minyak *Nigella sativa* melalui teknik *Supercritical Fluid Extraction (SFE)* dan ekstrak pelarut (methanol dan heksana), atau *Conjugated Equine Estrogen (CEE)* terhadap ciri-ciri menopause terpilih dan status metabolik tikus-tikus. Lima kumpulan tikus-tikus OVX dengan setiap satu kumpulan terdiri dari lapan ekor tikus diberi 300 mg/kilogram ekstrak berbeza *Nigella sativa* iaitu dari teknik *Supercritical Fluid Extraction(SFE)*, ekstrak pelarut metanol dan heksana atau CEE (0.2mg/kilogram). Kajian ketiga ialah bagi menentukan kandungan asid lemak dalam *Nigella sativa* iaitu asid linoleik (LA), asid gamma linolenik (GLA) serta sebatian minyak mudah meruap (volatile oil, thymoquinone TQ) dan mengenal pasti kesan sebatian-sebatian ini terhadap ciri-ciri putus haid terpilih dan status metabolik tikus-tikus teraruh menopause. Eksperimen ketiga mengandungi dua peringkat. Dalam peringkat 1, ekstrak pelbagai *Nigella sativa* dianalisis untuk menentukan kandungan asid lemak dan minyak meruap ruap (*volatile oil*) *Nigella sativa*. Dalam peringkat tikus OVX telah diberikan suplemen asid lemak (LA dan GLA) dan sebatian mudah meruap (TQ) yang terkandung dalam *Nigella sativa* dengan dos berikut: asid linoleik (50mg/kilogram), asid gamma linolenik (10mg/kilogram), dan thymoquinone (15mg/kilogram) atau

Conjugated Equine estrogen (0.2mg / kilogram) sebagai kawalan positif. Minyak zaitun (1ml/sehari) diberi sebagai kawalan negatif.

Keputusan bagi kajian pertama menunjukkan tikus-tikus yang menerima CEE dan peibagai dos *Nigella sativa*, mempunyai berat rahim yang lebih tinggi secara signifikan ($p < 0.05$) berbanding kumpulan kawalan (290 ± 0.01 - 500 ± 0.01 berbanding 190 ± 0.02 mg untuk NS dan CEE berbanding kawalan). Suplementasi dengan *Nigella sativa* juga merangsang perubahan histologi menyerupai kesan estrogen pada lapisan endometrium rahim berbanding kumpulan kawalan (ketebalan endometrium: 281 ± 39 dan 365 ± 123 berbanding 251 ± 107 μm untuk NS dan CEE berbanding kawalan). *Nigella sativa* pada dos yang rendah mampu mengaruh kesan seperti secara signifikan berbanding dos sederhana dan dos tinggi *Nigella sativa*. Kajian kedua pula menunjukkan ekstrak metanol *Nigella sativa* menunjukkan secara signifikan kesan estrogenik iaitu peningkatan peratus kornifikasi sel epitelium faraj dan peningkatan estrogen dan paras status metabolik berbanding heksana dan ekstrak dari SFE. Peratus kornifikasi sel faraj 47.62%, 32.87%, 32.46% untuk methanol, hexane dan SFE berbanding 62% dan 00% untuk masing-masing kawalan positif dan negatif). Kajian ketiga menunjukkan yang antara tiga sebatian aktif *Nigella sativa* [(asid linoleik (LA), asid gama linolenik (GLA) dan thymoquinone (TQ)], hanya LA mempunyai sifat menyerupai ($p < 0.05$) kesan-kesan estrogenic. Peratus konifikasi sel faraj 37.92%, 9.50%, 14.62%, 62% masing-masing untuk LA, GLA, TQ dan CEE berbanding 00% kawalan.

Dalam kajian ini, tikus-tikus OVX yang diberi supplemen *Nigella sativa* telah menunjukkan kesan menyerupai kesan estrogen dari segi parameter fizikal, histologi dan

biokimia. Sehubungan itu kajian ini telah menunjukkan kemungkinan *Nigella sativa* boleh berperanan dan bermanfaat di dalam rawatan gejala menapos.

Sebagai kesimpulan, kajian ini menunjukkan beberapa bukti baru menukong kepada penggunaan herba tradisional seperti *Nigella sativa* sebagai salah satu pilihan terapi penggantian hormon estrogen. Kajian-kajian di masa hadapan adalah diperlukan untuk menjelaskan prinsip, mekanisme serta pengetahuan di peringkat molekular mengenai proses yang bertanggungjawab terhadap kesan *Nigella sativa* dan sebatian aktifnya ke atas sistem reproduksi mamalia.

ACKNOWLEDGEMENTS

Foremost, I would like to thank Allah for being able to complete this research. I am grateful to Prof Dr Fatimah Mohd Yusoff, Director of Institute of Bioscience (IBS) and Prof. Dr. Azhar Md Zain, Dean of Faculty of Medicine and Health Sciences (FMHS), UPM for giving me the permission to run my research as one of the requirements for attaining the Doctor of Philosophy (Community Health). I would like to express my gratitude and appreciation to my supervisor, Associate Professor Dr. Latiffah A. Latiff for her guidance, advice, time and knowledge throughout the whole research project. This project would not be a success without her supervision and valuable input.

Special thanks also to my co-supervisors, Assoc. Prof. Dr. Sabariah Abdul Rahman, Assoc. Prof. Dr. Mohd. Aziz bin Dollah, Assoc. Prof. Dr. Rashid Ibrahim, Prof. Dr. Syed Tajuddin Syed Hassan and Dr. Parichehr Hanachi, for their encouragement, advice, inspiration, patience, and guidance throughout this project.

My gratitude to the staff of IBS and FPSK, UPM for their time and effort spent to participate in this research project as well as my fellow course-mates who helped when I encountered difficulties.

Last but not least, I would like to convey my greatest and deepest thanks and appreciation to my family for their love, care and emotional support throughout the period of conducting my research project.

I certify that a Thesis Examination Committee has met on 26th October 2009 to conduct the final examination of **Saadat Parhizkar** on her thesis entitled “**Effect of *Nigella sativa* on selected menopausal parameters in ovariectomized rats**” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the degree of Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Farida Fatema Farida Jamal, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairperson)

Sabrina Sukardi, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Abdul Manan Mat Jais, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Syed Mohsin Sahil Jamalullail, PhD

Professor
Universiti Sains Malaysia
(External Examiner)

BUJANG BIN KIM HUAT, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 24 December 2009

This thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Latiffah Abdul Latiff, MD, MPH, M.Sc.

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairperson)

Mohammad Aziz Dollah, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Sabariah Abdul Rahman, MBBS, M.Path, AM.

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Rashid Ibrahim, DVM, PhD

Associate Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

Hassan Syed Tajuddin, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Parichehr Hanachi, PhD

Women Research Center
University Al-Zahra, Iran
(Member)

HASANAH MOHD GHAZALI, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 14 January 2010

DECLARATION

I declare that this thesis is my original work except for quotations and citation which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.



SAADAT PARHIZKAR

Date: 5 February 2010

TABLE OF CONTENTS

| | Page |
|---|-------------|
| ABSTRACT | iii |
| ABSTRAK | vi |
| ACKNOWLEDGEMENTS | x |
| APPROVAL | xi |
| DECLARATION | xiii |
| TABLE OF CONTENTS | xiv |
| LIST OF TABLES | xix |
| LIST OF FIGURES | xxii |
| LIST OF ABBREVIATIONS | i |
| CHAPTER | |
| 1 INTRODUCTION | 1 |
| 1.1 Background | 1 |
| 1.2 Problem Statement | 4 |
| 1.3 Scope of the Study | 7 |
| 1.4 The use of rodents as an OVX model | 10 |
| 1.5 Objectives | 13 |
| 1.5.1 General Objectives | 13 |
| 1.5.2 Specific Objectives | 13 |
| 1.6 Research Hypothesis | 14 |
| 2 LITERATURE REVIEW | 15 |
| 2.1 Menopause | 15 |
| 2.1.1 Epidemiology | 17 |
| 2.1.2 Functional Development of Reproductive System in Women | 20 |
| 2.1.3 The normal menstrual cycle in women during the reproductive years | 24 |
| 2.1.4 Rat Reproductive cycle | 25 |
| 2.1.5 Mechanism of action of steroid hormones | 33 |
| 2.1.6 Menopause and effects on human health | 41 |
| 2.2 Menopausal Symptoms | 42 |
| 2.2.1 Immediate post-menopausal symptoms | 43 |
| 2.2.2 Late post-menopausal symptoms | 45 |
| 2.3 Management of postmenopausal symptoms | 49 |
| 2.3.1 Lifestyle Modifications | 50 |
| 2.3.2 Hormone Replacement Therapy | 53 |
| 2.3.3 Non-hormonal alternatives | 63 |
| 2.3.4 Complementary Approaches | 65 |
| 2.4 <i>Nigella sativa</i> | 71 |
| 2.4.1 Characteristics and its effects on body system | 71 |

| | | |
|----------|---|-----------|
| | 2.4.2 Plant Description and Cultivation | 72 |
| | 2.4.3 Physical and Chemical properties of <i>Nigella sativa</i> | 73 |
| | 2.4.4 Nutrient Composition of <i>Nigella sativa</i> | 74 |
| | 2.4.5 Vitamin Composition of <i>Nigella sativa</i> | 75 |
| | 2.4.6 Amino Acid of <i>Nigella sativa</i> | 76 |
| | 2.4.7 Fatty acid composition of <i>Nigella sativa</i> | 77 |
| | 2.4.8 Sterol composition of <i>Nigella sativa</i> | 77 |
| | 2.4.9 General Health Benefits of <i>Nigella sativa</i> | 78 |
| | 2.4.10 Effect of <i>Nigella sativa</i> on female reproductive System | 81 |
| | 2.4.11 Effect of <i>Nigella sativa</i> on male reproductive System | 84 |
| | 2.4.12 Effect of <i>Nigella sativa</i> on postmenopausal symptoms | 85 |
| 3 | MATERIALS AND METHODS | 87 |
| | 3.1 Study Protocol | 86 |
| | 3.2 Experiment I: Evaluation of the effects of different doses of <i>Nigella sativa</i> seeds on selected menopausal characteristics of menopause-induced rats | 89 |
| | 3.2.1 Materials | 89 |
| | (i) Plant Materials | 89 |
| | (ii) Chemicals and Reagents | 90 |
| | (iii) Experimental Animals | 90 |
| | 3.2.2 Methods | 91 |
| | (i) Experimental Design | 91 |
| | (ii) Ovariectomy | 92 |
| | (iii) Parameters | 93 |
| | (1) Vaginal Smear | 93 |
| | (2) Blood Collection | 93 |
| | (3) Blood Analysis | 94 |
| | a) Lipid Profile | 94 |
| | b) Blood Glucose | 94 |
| | c) Blood Estradiol | 95 |
| | (4) Food and water intakes and Body Weight Measurement | 95 |
| | (5) Post-mortem and Uterine Horn Histological Study | 95 |
| | (6) Sampling protocol | 96 |
| | 3.2.3 Statistical Analysis | 97 |
| | 3.3 Experiment II. Evaluation of the effects of different crude oil extracts of <i>Nigella sativa</i> on selected menopausal characteristics of menopause-induced rats | 98 |
| | 3.3.1 Materials | 98 |
| | (i) Plant Materials | 98 |
| | (ii) <i>Nigella sativa</i> Extracts | 98 |
| | a) Preparation of Methanol Extract | 98 |
| | b) Preparation of Hexane Extract | 99 |
| | c) Supercritical Fluid Extraction (SFE) | 99 |

| | |
|---|-----|
| (iii) Chemicals and Reagents | 100 |
| (iv) Experimental Animals | 100 |
| 3.3.2 Methods | 100 |
| (i) Experimental Design | 100 |
| (ii) Ovariectomy | 101 |
| (iii) Parameters | 101 |
| (1) Vaginal Smear | 101 |
| (2) Blood Collection and Analysis | 102 |
| (3) Food and water intakes and Body Weight Measurement | 102 |
| 3.3.3 Statistical Analysis | 102 |
| 3.4 Experiment III. Evaluation of the effects of three different ingredients of <i>Nigella sativa</i> on selected menopausal characteristics of menopause-induced rats | 103 |
| 3.4.1 Materials | 103 |
| (i) Chemicals and Reagents | 103 |
| (ii) Experimental Animals | 103 |
| 3.4.2 Methods | 104 |
| (ii) Methods of Extraction of <i>Nigella sativa</i> | 104 |
| (iii) Determination of fatty acid composition of <i>Nigella sativa</i> using Gas Chromatography-Flame Ionization Detector (GC-FID) Analysis | 104 |
| (iii) Experimental Design | 106 |
| 4 RESULTS | 108 |
| 4.1 Experiment I: Evaluation of the effects of different doses of <i>Nigella sativa</i> seeds on selected menopausal characteristics of menopause induced rats | 108 |
| 4.1.1 Body weight | 108 |
| 4.1.2 Lipid profile | 111 |
| 4.1.3 Blood Glucose | 117 |
| 4.1.4 Serum Estradiol | 119 |
| 4.1.5 Cornification of Vaginal Epithelial Cells | 121 |
| 4.1.6 Rats' Uteri | 125 |
| (i) Uterus weight | 125 |
| (ii) Morphologic Analysis | 127 |
| 4.2 Experiment II. Evaluation of the effects of different crude oil extracts of <i>Nigella sativa</i> on selected menopausal characteristics of menopause induced rats | 135 |
| 4.2.1 Body weight | 135 |
| 4.2.2 Lipid profile | 137 |
| 4.2.3 Blood Glucose | 144 |
| 4.2.4 Effect of different crude oil extracts of <i>Nigella sativa</i> on Serum Estradiol | 146 |

| | | |
|------------|---|-----|
| 4.2.5 | Cornification of vaginal Epithelial Cells | 148 |
| 4.3 | Experiment III. Evaluation of the effects of three different ingredients of <i>Nigella sativa</i> on selected menopausal characteristics of menopause-induced rats | 152 |
| 4.3.1 | Fatty Acid composition and GC profiling of <i>Nigella sativa</i> | 152 |
| 4.3.2 | Body weight | 155 |
| 4.3.3 | Lipid profile | 156 |
| 4.3.4 | Blood Glucose | 163 |
| 4.3.5 | Serum Estradiol | 165 |
| 4.3.6 | Cornification of vaginal Epithelial Cells | 167 |
| 5 | DISCUSSION | 171 |
| 5.1 | Experiment I: Evaluation of the effects of different doses of <i>Nigella sativa</i> seeds on selected menopausal characteristics of menopause induced rats | 171 |
| 5.1.1 | Metabolic Status | 171 |
| 5.1.2 | Menopausal Parameters | 178 |
| 5.2 | Experiment II. Evaluation of the effects of different crude oil extracts of <i>Nigella sativa</i> on selected menopausal characteristics of menopause induced rats | 184 |
| 5.2.1 | Metabolic Status | 184 |
| 5.2.2 | Menopausal Parameters | 187 |
| 5.3 | Experiment III. Evaluation of the effects of three different ingredients of <i>Nigella sativa</i> on selected menopausal characteristics of menopause-induced rats | 189 |
| 5.3.1 | Metabolic Status | 191 |
| 5.3.2 | Menopausal Parameters | 195 |
| 6 | CONCLUSION AND RECOMMENDATIONS | 201 |
| 6.1 | General Discussion | 201 |
| 6.2 | Conclusion | 206 |
| 6.3 | Strengths and Limitations of the study | 207 |
| 6.4 | Recommendations | 209 |
| | REFERENCES | 210 |
| | APPENDICES | 252 |
| | BIODATA OF STUDENT | 285 |
| | LIST OF PUBLICATIONS | 286 |

LIST OF TABLES

| Table | | Page |
|--------------|--|-------------|
| 2.1 | Sex Ratio among People Aged 60 years and above by Age Group, 1970–2020 | 19 |
| 2.2 | Summary of the defining histological features of the rat female reproductive tract during diestrus, proestrus, estrus, and metestrus | 26 |
| 2.3 | Biological effects of estrogen | 37 |
| 2.4 | Biological effect of progesterone | 38 |
| 2.5 | Biological effects of androgen | 38 |
| 2.6 | Frequency of the most common Climacteric symptoms | 43 |
| 2.7 | Some characteristics of <i>Nigella Sativa</i> | 74 |
| 2.8 | Mineral contents of <i>Nigella Sativa</i> , as reported in the literature | 75 |
| 2.9 | Vitamin Composition of <i>Nigella Sativa</i> , as reported in the literature | 75 |
| 2.10 | Amino acid content of <i>Nigella Sativa</i> | 76 |
| 2.11 | Fatty Acid Composition of <i>Nigella Sativa</i> | 77 |
| 2.12 | Sterol composition (% total sterols) of <i>Nigella sativa</i> seed oils | 78 |
| 3.1 | Experimental design used to study the effect of various doses of <i>Nigella sativa</i> supplementation on selected menopausal characteristics of menopause-induced rats. | 92 |
| 3.2 | Experimental design used to study the effects of different extracts of <i>Nigella sativa</i> on selected menopausal characteristics of menopause-induced rats | 101 |
| 3.3 | Experimental design used to study the effect of various ingredients of <i>Nigella sativa</i> on selected menopausal characteristics of OVX rats. | 107 |
| 4.1 | ANOVA for body weight of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 110 |
| 4.2 | Mean of Average Daily Gain (gram) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 110 |
| 4.3 | GLM of Average Daily Gain (gram) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 111 |
| 4.4 | Mean of total cholesterol concentration (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 111 |
| 4.5 | ANOVA for TC level of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 112 |
| 4.6 | ANOVA for TG level of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 113 |
| 4.7 | ANOVA for HDL level of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 115 |
| 4.8 | Mean of Low Density Lipoprotein (LDL) concentration (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 116 |
| 4.9 | ANOVA for LDL level of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 116 |
| 4.10 | Mean of Lipid Profile level (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 117 |

| | | |
|------|--|-----|
| 4.11 | ANOVA for Blood Glucose level of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 119 |
| 4.12 | ANOVA for Estradiol concentration of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 121 |
| 4.13 | Mean of Vaginal Cornified cell percent of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 121 |
| 4.14 | ANOVA for Vaginal Cornified cell percent of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 122 |
| 4.15 | Mean of uterus wet and relative weight of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 126 |
| 4.16 | Summary of Physiologic and morphologic finding in uteri of ovariectomized rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 132 |
| 4.17 | ANOVA for Body Weight of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 136 |
| 4.18 | ANOVA for total cholesterol of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 139 |
| 4.19 | ANOVA for triglyceride of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 141 |
| 4.20 | Means of High Density Lipoprotein (HDL) (mmol/L) concentration of OVX rats supplemented with various Extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 141 |
| 4.21 | ANOVA for High Density Lipoprotein (HDL) of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 142 |
| 4.22 | Means of Low Density Lipoprotein (LDL) (mmol/L) concentration of OVX rats supplemented with various Extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 143 |
| 4.23 | ANOVA for Low Density Lipoprotein (LDL) of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 143 |
| 4.24 | Lipid Profile level (mmol/L) of OVX rats at different days of supplementation with various Extract of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 144 |
| 4.25 | ANOVA for Serum Glucose of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 146 |
| 4.26 | Mean of serum estradiol (pg/ml) concentration of OVX rats supplemented with various Extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 147 |
| 4.27 | ANOVA for serum estradiol of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 147 |
| 4.28 | Mean of Vaginal Cornified cell percent of OVX rats supplemented with various Extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 148 |

| | | |
|-------|--|-----|
| 4.29 | ANOVA for Vaginal Cornified cell percent of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 149 |
| 4.30 | Fatty acid composition of three different extracts of <i>Nigella sativa</i> | 154 |
| 4.31 | ANOVA for Body Weight of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 156 |
| 4.32 | Mean of total cholesterol (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 157 |
| 4.33 | ANOVA for Total Cholesterol of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 157 |
| 4.34 | ANOVA for Triglyceride of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 159 |
| 4.35 | ANOVA for High Density Lipoprotein (HDL) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 161 |
| 4.36 | Mean of Low Density Lipoprotein (LDL) (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 161 |
| 4.37 | ANOVA for Low Density Lipoprotein (LDL) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 162 |
| 4.38 | Lipid Profile level (mmol/L) of OVX rats at different days of supplementation with various Ingredient of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 163 |
| 4.39 | ANOVA for serum glucose of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 164 |
| 4.40 | Mean of serum estradiol (pg/ml) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 166 |
| 4.41 | ANOVA for serum estradiol of OVX rats supplemented with various Active ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 166 |
| 4.42 | Mean of Vaginal Cornified Cell percent of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen | 167 |
| 4.43 | ANOVA for Vaginal Cornified Cell percent of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 168 |
| 5.1 | Fatty acids inhibit [3H]-estradiol from binding to estrogen receptors α and β . | 199 |
| app 1 | Tissue dehydration in a tissue processor machine | 270 |
| app 2 | Coloration with Hematoxyline and Eosin | 272 |
| app 3 | Means body weight (gram) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 278 |
| app 4 | Means of triglyceride concentration (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 278 |

| | | |
|--------|---|-----|
| app 5 | Means of High Density Lipoprotein (HDL) concentration (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 279 |
| app 6 | Means of blood glucose concentration (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 279 |
| app 7 | Means of serum estradiol concentration (pg/ml) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 280 |
| app 8 | Means of body weight (gram) of OVX rats supplemented with extracts from various methods of extraction of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 280 |
| app 9 | Means of total cholesterol (mmol/L) concentration of OVX rats supplemented with some extracts of <i>Nigella sativa</i> obtained from various methods of extraction or Conjugated Equine Estrogen. | 281 |
| app 10 | Means of triglyceride (mmol/L) concentration of OVX rats supplemented with extract from various methods of extraction of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 281 |
| app 11 | Means of serum glucose (mmol/L) concentration of OVX rats supplemented with extract from various methods of extraction of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 282 |
| app 12 | Means of body weight (gram) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 282 |
| app 13 | Means of triglyceride (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 283 |
| app 14 | Means of High Density Lipoprotein (HDL) (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 283 |
| app 15 | Means of serum glucose (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 284 |

LIST OF FIGURES

| Figure | | Page |
|--------|---|------|
| 2.1 | Schematic diagram of female hypothalamic–pituitary–gonadal axis. | 21 |
| 2.2 | This schematic illustrates the estrus cycle patterns in rats and the effect of aging on it. | 28 |
| 2.3 | Vaginal smear of adult rats during proestrus phase. | 30 |
| 2.4 | Vaginal smears of adult rats during estrus phase | 30 |
| 2.5 | Vaginal smears of adult rats during Metestrus phase | 31 |
| 2.6 | Vaginal smears of adult rats during Detestrus phase | 31 |
| 2.7 | Comparison of The human reproductive cycle | 33 |
| 2.8 | Mechanism of action of steroid hormones | 34 |
| 2.9 | Molecular Structure of endogenous estrogen | 36 |
| 2.10 | Synthesis of postmenopausal estrogens | 41 |
| 2.11 | <i>Nigella sativa</i> | 73 |
| 3.1 | Flow diagram of the experimental studies to determine the effect of <i>Nigella sativa</i> on selected menopausal characteristics of menopause-induced rats | 88 |
| 4.1 | Body weight changes among rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 days. | 109 |
| 4.2 | Changes of serum triglyceride level (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 113 |
| 4.3 | Changes of serum HDL level (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 114 |
| 4.4 | Changes of serum glucose level (mmol/L) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 118 |
| 4.5 | Changes of serum estradiol level (pg/ml) of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 120 |
| 4.6 | Vaginal smear of ovariectomized rat from control group treated with distilled water for 3 weeks. | 122 |
| 4.7 | Vaginal smear of ovariectomized rat treated with Conjugated Equine Estrogen (0.2 mg/kg) for 3 weeks. | 123 |
| 4.8 | Vaginal smear of ovariectomized rat treated with Low dose of <i>Nigella sativa</i> (300 mg/kg) for 3 weeks | 123 |
| 4.9 | Vaginal smear of ovariectomized rat treated with Medium dose of <i>Nigella sativa</i> (600 mg/kg)for 3 weeks | 124 |
| 4.10 | Vaginal smear of ovariectomized rat treated with High dose of <i>Nigella sativa</i> (1200 mg/kg) for 3 weeks | 124 |
| 4.11 | Photographs of uteri excised from rats treated with <i>Nigella sativa</i> , Conjugated Equine Estrogen or vehicle | 125 |
| 4.12 | Means of uterus relative weight of OVX rats (mg/100 gm body weight) supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 126 |
| 4.13 | Photomicrographs showing representative uterus of OVX rats | 129 |

| | | |
|------|--|-----|
| 4.14 | Photomicrographs showing representative endometrium of the uterus of ovariectomized rats | 130 |
| 4.15 | Photomicrography showing representative endometrium of ovariectomized rats | 131 |
| 4.16 | Means of Endometrial and Myometrial Thickness (μm) in Uteri of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 133 |
| 4.17 | Means of Luminal and Glandular Epithelial Cell Height (μm) in Uteri of OVX rats supplemented with various doses of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 134 |
| 4.18 | Changes of body weight (gm) of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen. | 136 |
| 4.19 | Changes of serum total cholesterol level (mmol/L) of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 138 |
| 4.20 | Changes of serum triglyceride level (mmol/L) of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 140 |
| 4.21 | Changes of serum glucose level (mmol/L) of OVX rats supplemented with various extracts of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 145 |
| 4.22 | Vaginal smear of ovariectomized rat treated with Supercritical Fluid Extraction of <i>Nigella sativa</i> (300 mg/kg) for 3 weeks. | 149 |
| 4.23 | Vaginal smear of ovariectomized rat treated with Methanol Extract of <i>Nigella sativa</i> (300 mg/kg) for 3 week | 150 |
| 4.24 | Vaginal smear of ovariectomized rat treated with Hexane Extract of <i>Nigella sativa</i> (300 mg/kg) for 3 weeks. | 150 |
| 4.25 | Vaginal smear of ovariectomized rat treated with Conjugated Equine Estrogen (0.2 mg/kg)for 3 weeks. | 151 |
| 4.26 | Vaginal smear of ovariectomized rat from control group treated with Olive Oil for 3 weeks. | 151 |
| 4.27 | GC profiling of fatty acid composition of Methanol extract of <i>Nigella sativa</i> | 152 |
| 4.28 | GC profiling of fatty acid composition of SFE extract of <i>Nigella sativa</i> | 153 |
| 4.29 | GC profiling of fatty acid composition of Hexane extract of <i>Nigella sativa</i> | 153 |
| 4.30 | Changes of body weight (gm) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 155 |
| 4.31 | Changes of serum triglyceride level (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 158 |
| 4.32 | Changes of serum HDL level (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 160 |

| | | |
|-------|---|-----|
| 4.33 | Changes of serum glucose level (mmol/L) of OVX rats supplemented with various ingredients of <i>Nigella sativa</i> or Conjugated Equine Estrogen for 21 Days. | 164 |
| 4.34 | Vaginal smear of ovariectomized rat treated with Thymoquinone (15mg/kg) for 3 weeks. | 168 |
| 4.35 | Vaginal smear of ovariectomized rat treated with Conjugated Equine Estrogen (0.2 mg/kg) for 3 weeks. | 169 |
| 4.37 | Vaginal smear of ovariectomized rat treated with Linoleic Acid (50mg/kg) for 3 weeks. | 169 |
| 4.38 | Vaginal smear of ovariectomized rat treated with Gamma Linoleic Acid (10mg/kg) for 3 weeks. | 170 |
| 4.39 | Vaginal smear of ovariectomized rat from control group treated with Olive Oil for 3 weeks | 170 |
| 5.1 | Possible mechanisms for the role of polyunsaturated fatty acids on reproductive function in dairy cows | 198 |
| app B | Notice of Approval by Animal Care and Use Committee (ACUC), Faculty of Medicine and Health Sciences, University Putra Malaysia. | 255 |
| app B | ACUC Approval | 256 |
| app 1 | Schematic diagram showing the surgical removal of the ovaries | 258 |
| app 2 | Ovariectomy procedures. Removal of right ovary after removing left ovary. | 259 |
| app 3 | The removal and preparation of the uterine tissues for weight measurement. | 269 |
| app 4 | A proposed model showing how an orientation of cell division can influence the shape of a gland in the uterus. | 275 |

LIST OF ABBREVIATIONS

| | |
|--------------------------------|---|
| AACE | American Association of Clinical Endocrinologists |
| ACOG | American College of Obstetricians and Gynecologists |
| ACUC | Animal Care and Use Committee |
| ADG | Average Daily Gain |
| AE | Anestrus |
| app | Appendix |
| ANOVA | Analysis of Variance |
| B.C. | Before Christ |
| BBT | Basal Body Temperature |
| BMD | Bone Mass Density |
| BS | Black Seed |
| BW | Body Weight |
| C | Celsius/Centigrade |
| cm. | centimeter |
| CAM | Complementary and Alternative Medicine |
| CE | constant estrus |
| CEE | Conjugated Equine Estrogen |
| CHD | Coronary Heart Disease |
| CLA | Conjugated Linoleic Acid |
| CM | Cloroform-Methanol |
| CRP | C-reactive protein |
| CSA | Cross-Sectional Area |
| CVD | Cardiovascular disease |
| CYP7α | Cholesterol 7 α -hydroxylase |
| df | Degree of Freedom |
| DH2O | Distilled Water |
| DHEA | Dehydroepiandrosterone |
| DHEAS | Dehydroepiandrosterone sulfate |
| DHT | Dihydrotestosterone |
| DMRT | Duncan Multiple Range Test |

| | |
|-----------------------------------|--|
| DNA | DeoxyriboNucleic Acid |
| DPX | Distyrene plasticizer xylene |
| DSL | Diagnostic Systems Laboratories |
| DVT | Deep Vein Thrombosis |
| E1 | Estrone |
| et al. | et alia (Latin), which means “and others.” |
| E2 | Estradiol |
| E3 | Estriol |
| EPO | Erythropoietin |
| EPT | Estrogen-Progestin Therapy |
| ER | Estrogrn Receptor |
| ERs | Estrogen Receptors |
| ERT | Estrogen replacement therapy |
| ET | Estrogen therapy |
| FAME | Fatty Acid Methyl Esters |
| FBS | Fast Blood Sugar |
| FDA | Food and Drug Administration |
| FFA | Free Fatty Acid |
| Fig. | Figure |
| FHMS | Faculty of Medicine and Health Sciences |
| FMP | Final menstrual period |
| FPSK | Fakulti Perubatan dan Sains Kesihatan |
| FSH | Follicle Stimulating Hormone |
| FSH | Follicle Stimulating Hormone |
| G. | Gauge |
| GC-FID | Gas Chromatography/Flame Ionization Detector |
| GLA, γLA | Gamma Linolenic |
| GLM | General Linear Model |
| GnRH | Gonadotropine releasing Hormone |
| h | Hour |
| HDL | High Density Lipoprotein |

| | |
|--------------|--|
| HERS | Heart and Estrogen-Progestin Replacement Study |
| HRT | Hormone replacement therapy |
| HT | Hormone Therapy |
| IC50 | 50% Inhibitory Concentration |
| i.e. | id est (Latin), which means 'that is' |
| IP | Intraperitoneally |
| IU | International unit |
| LA | Linoleic Acid |
| LDL-C | Low Density Lipoprotein-Cholesterol |
| LDL | Low Density Lipoprotein |
| LDLR | Low Density Lipoprotein receptors |
| LF | Low Fat |
| LH | Luteinizing Hormone |
| LHRH | Luteinizing Hormone-Releasing Hormone |
| MPA | Medroxyprogesterone |
| mRNA | Messenger Ribonucleic Acid |
| MPa | MegaPascal (unit of pressure) |
| MUFA | Monounsaturated Fatty acid |
| NAMS | North American menopause Society |
| NCCAM | National Center for Complementary and Alternative Medicine |
| NHLBI | National Heart, Lung, and Blood Institute |
| NHPs | Nonhuman primates |
| NS | <i>Nigella sativa</i> |
| NSB | Non Specific Binding |
| NSO | <i>Nigella sativa</i> Oil |
| NSW | New South Wales |
| OECD | Organization for Economic Cooperation and Development |
| OH | Hydroxyl |
| OVX | Ovariectomized |
| PD | Persistent Diestrus |
| PE | Pulmonary Embolus |

| | |
|------------------------|---|
| PGE₂ | Prostaglandin E2 |
| pmol/l | Picomoles per Liter |
| PPAR | Peroxisome Proliferators-Activated Receptor |
| PUFA | Polyunsaturated Fatty Acid |
| RCTs | Randomized Clinical Trials |
| REE | Reduced Energy Expenditure |
| RIA | Radioimmunoassay |
| RNA | Ribonucleic acid |
| rpm | Revolutions (or rotations) per minute |
| RR | Relative Risk |
| SAS | Statistical Analysis Software |
| SD | Standard Deviation |
| SERMs | Selective estrogen-receptor modulators |
| SFE | Supercritical Fluid Extraction |
| SHBG | Sex Hormone-Binding Globulin |
| SPSS | Statistical Package for the Social Sciences |
| SSRIs | Selective Serotonin Reuptake Inhibitors |
| STRAW | Stages of Reproductive Aging Workshop |
| TC | Total Cholesterol |
| TG | Triglyceride |
| TQ | Thymoquinone |
| TSFA | Total Saturated Fatty acid |
| TUFA | Total unsaturated Fatty acid |
| UPM | Univerciti Putra Malaysia |
| UV | Ultraviolet |
| VMS | Vasomotor Symptoms |
| VTE | Venous Thromboembolism |
| w/v | Weight/volume |
| WHI | Women's Health Initiative |
| WHIMS | Women's Health Initiative Memory Study |
| WHO | World Health Organization |



CHAPTER 1

INTRODUCTION

1.1 Background

The use of natural products with therapeutic properties is as ancient as human civilization and for a long time, mineral, plant and animal products were the main source of drugs used for reproductive purpose (Hernandez-Ceruelos *et al.*, 2002). Plants have always been a major source of nutrition and health care for both humans and animals. The writings on nutritional and medicinal plants started as early as before 1500 B.C. in Egypt, 800-400 B.C. in Indo-Pakistan, and 500 B.C. in China. In recent years, there has been growing interest in alternative therapies and the therapeutic use of natural products, especially those derived from plants (Schwartzmann *et al.*, 2002). However, scientific research interest in medicinal plants received a thrust during the mid-1970s when World Health Organization (WHO) proposed the incorporation of traditional medicine into the health care system. In 1978, World Health Assembly called for a comprehensive approach to the medicinal plants that include the designation of research and training centers for the study and use of medicinal plants (Anwar, 2005).

The *Nigella sativa* (black seed) is a type of plant that belongs to the *Ranunculaceae* family (El-Dakhakhny *et al.*, 2000). It has been used as a herbal medicine for more than 2000 years. Ibn Sina (Avicenna 980-1037), is most famous for his publications called 'The Law of Medicine' regarded by many as the most famous book in the history of medicine, refers Black seed as the seed that stimulates the body's energy and helps recovery from fatigue or dispiritedness as well as gynecologic disorders (Sharafkhandy, 1990). It is also used as a food additive and flavoring agent in many countries. The black seed oil is reported to be beneficial due to its content of over a hundred components such as aromatic oils, trace elements, and vitamins (Ali and Blunden, 2003).

Recently, clinical and animal studies have shown that extract of the black seeds have many therapeutic effects such as immunomodulative (Hanafy and Hatem, 1991), antibacterial (Zaoui *et al.*, 2000), anti-tumor (Turkdogan *et al.*, 2001), diuretic and hypotensive (Kanter *et al.*, 2003), hepatoprotective and antidiabetic (Houghton *et al.*, 1995; Kanter *et al.*, 2003).

The seeds contain both fixed and essential oils, proteins, alkaloids and saponin. Much of the biological activity of the seeds has been shown to be due to thymoquinone, the major component of the essential oil which is also present in the fixed oil (Badary *et al.*, 2002).

The pharmacological actions of the crude extracts of the seeds (and some of its active constituents, e.g. volatile oil and thymoquinone) that have been reported include protection against nephrotoxicity and hepatotoxicity induced by either disease or chemicals (Zaoui *et al.*, 2002).

Rhandhawa and Al-Ghamdi (2002) stated that the multiple use of *Nigella sativa* in folk medicine encouraged many investigators to isolate the possible active components and to conduct *in vitro* and *in vivo* studies on laboratory animals and human beings in order to understand its pharmacological actions. One of the components of fixed oils is the sterols. Sterols are steroids containing 27 or more carbon atoms with an OH [hydroxyl] group. A remarkable number of 23 sterols have been identified in the seed. As several of human and animal hormones also have steroidal structures, plant steroids with structural features which fit onto the hormone receptors can exert many bio-activities related to corticosteroids or the sex hormones. Because of the variety of steroidal structures present in the seed, the full extent of the seeds' action on the hormonal system can only be speculated upon at this stage (Norton, 1998).

Nigella sativa is also accepted in folk medicine as estrogenic activity which can help regulate menstrual cycles in women. Since estrogen plays an important role in regulating various body systems in the female, drastic change or reduction in estrogen levels can result in elevated blood pressure, increased glucose intolerance and dyslipidemia which may lead to development of metabolic syndrome. As a traditional medicine, *Nigella sativa* increases milk production and promotes menstruation in the female (Sharafkhandy, 1990); however there are no detail information on its effect on the reproductive system.

1.2 Problem Statement

Menopause is the period in a woman's life when hormonal changes cause menstruation to cease permanently (Andrews, 1995) and it is a natural part of the aging process. The World Health Organization (WHO) reported that by 2030, there will be 1.2 billion women at and over the age of 50. Therefore, although menopause seems like a natural process, it is a period that must definitely be followed and treated (Browngoehl, 2000). The experience of menopause varies greatly from one woman to another. For some, it is completely symptom free. Others may require assistance to cope with physical and psychological effects of menopause. For women requiring assistance, a range of options and supports are available such as lifestyle changes, medical treatments and complementary approaches (Bones, 2006).

According to WHO report (1996), at the end of the 19th century life expectancy for women was about 50 years, but nowadays it has risen to more than 80 years and in some countries such as Japan, women have a life expectancy of 86 years. The age of menopause, by contrast, has risen only slightly in this time, and occurs at about age 52. This means that in this day and age, women spend about one third of their life living in an estrogen-deficient state, which has far-reaching consequences for various organ systems and can result in a multitude of clinical problems. Clearly, the health concerns of menopause-aged women are rapidly becoming a public health priority (Lobo, 2000). Up to 75% of Malaysian women will experience five or more unpleasant menopausal symptoms such as atypical and classical symptoms during the menopausal transition (Dhillon *et al.*, 2006).

Menopause, whether natural or surgically induced, is associated with elevated levels of circulating total cholesterol and LDL cholesterol (LDL-C), placing postmenopausal women at greater risk for coronary heart disease (CHD) (Fukami *et al.*, 1995; Bruschi *et al.*, 1996; Grodstein *et al.*, 1996; Sullivan and Newman, 1996). Women who develop menopause have to deal with hormonal changes that affect both their blood sugar levels and body weight gain. These changes are the consequences of the reduction in the level of circulating estrogen. The mechanism through which a reduced level of circulating estrogen elevates the plasma cholesterol level is poorly understood. Reductions in the activity of hepatic LDL receptors (LDLR) (Brown and Goldstein, 1980; Walsh *et al.*, 1991; Riedel *et al.*, 2003) and/or cholesterol 7 α -hydroxylase (CYP7 α) activity (Deliconstantinos and Ramantanis, 1982; Kushwaha *et al.*, 1991) are presumably involved.

Depending on the disorder of ovarian function and, therefore, lack of estrogen in the postmenopausal period, symptoms such as hot flashes, irritability, sleeping disorders, fatigue, anxiety, loss of concentration are observed in the early period. Risk of coronary artery disease and incidence rate of osteoporosis increase due to the loss of protective effects of estrogen will occur in the late period. These symptoms in the postmenopausal period adversely affect the quality of life of woman. If we assume menopausal age as beginning at 50, women will spend 1/3 of their lives with the pathological changes they are exposed to in the postmenopausal period (Vandenakker and Glass, 2002; Messinger, 2002).

Hormone replacement treatment (HRT) is used as a standard therapy in menopausal treatment (Teoman *et al.*, 2004). Estrogen replacement therapy (ERT) in postmenopausal women reduces the risk of CHD in part by modulating serum cholesterol (Contreras and Parra, 2000; Petteti, 2003). However, HRT and cholesterol-lowering pharmacologic agents may be accompanied by side effects. The National Heart, Lung, and Blood Institute (NHLBI) study suggest that HRT regimens not only lead to increased risk of adverse events, but also they seem to provide little or no protective effects (Zunin and Bregman, 2002). Current guidance from the US Food and Drug Administration (FDA) states that estrogen plus progestin or estrogen alone should be used at the lowest possible dose for the shortest period of time. However, even over short durations (up to 5 years), estrogen plus progestin or estrogen alone (in women with or without a uterus, respectively) increases the risks of stroke (Rossouw *et al.*, 2002; Anderson *et al.*, 2004) dementia (Shumaker *et al.*, 2004); in women who have not had a hysterectomy, estrogen plus progestin additionally increases the risks of thromboembolic disease, coronary events, and breast cancer (Sherman *et al.*, 2005). Such findings have serious health and financial implications for all women facing decisions about therapy for menopausal symptoms, and the health care system must accept the need to look into other therapies for women's needs.

The effects of complementary alternative medicines (CAMs) in preventing the postmenopausal symptoms as another aspect of treatment are widely accepted today. In the context of menopause, CAMs have the potential to alleviate symptoms as well as improve general health status and quality of life. In relation to menopausal symptoms, studies have been undertaken on the clinical effectiveness of phytoestrogens (Albertazzi

et al., 1998; Drapier Faure *et al.*, 2002; Van de Weijer and Barentsen, 2002) and herbal therapies such as Chinese herbs (Davis *et al.*, 2001), dong quai (Hirata *et al.*, 1997), and evening primrose oil (Chenoy *et al.*, 1994). Numerous studies suggest that *Nigella sativa* as an amazing and multidimensional herb that has beneficial effects on cholesterol metabolism by improving the effects that hypercholesterolemia exert (Haq *et al.*, 1995; Bamosa, 1997; Buriro and Tayyab, 2007). On the other hand, based on its traditional use for promoting lactation and menstrual disorders, *Nigella sativa* is thought to be effective in improving hormonal deficiency such as menopausal symptoms. However *Nigella sativa* is quite safe and there is little concern about the side effects of excessive intake of *Nigella sativa* and the benefits outweigh its side effects. Due to probable risks of HRT and high cost of those treatments, herbal remedies particularly use of *Nigella sativa* may be a safe, cheap and effective treatment to control the symptoms of menopause.

1.3 Scope of the study

Menopause can represent a “choice point” or a preferred time for women to consider ways to improve their current health status and decrease the risk of long term illnesses (Mac Laren *et al.*, 2001; Taylor, 2001). Most women suffer from hormonal imbalances at some time during their reproductive, peri-menopausal and postmenopausal life. For the last decade or so, synthetic forms of hormone replacement therapy (HRT) have been the most prescribed treatment for peri-menopausal and postmenopausal women to reduce or eliminate uncomfortable symptoms that result from hormonal imbalances. However, the Women's Health Initiative (WHI) trial for HRT was terminated early

because of safety concerns and the Cancer Council of New South Wales (NSW) called for preventative hormone replacement to be suspended, because the study found that women were at greater risk of developing breast cancer and heart disease (Stapleton, 2008). As HRT was found to have treatment limitations and a higher risk to develop cancer, women are looking for other forms of treatment of menopausal symptoms and problems and they are turning to complementary and alternative medicine (CAM). The treatment of choice in complementary medicine is supplementation with herbal remedies (Boronditsky, 2000). The identification of an alternative agent, which has the beneficial effects of estrogen but has low cancer risk and side effects, would, therefore, be of considerable value.

In the context of menopause, Complementary and Alternative Medicines (CAMs) have the potential to alleviate symptoms as well as improve general health status. Yet few studies have been conducted on the use of CAMs among menopausal women, particularly the types, prevalence, and factors associated with CAM use. CAMs can be broadly grouped into CAM medications (ingestible) or therapies (non-ingestible) and include nutritional supplements, vitamins, and herbal supplements, as well as yoga, meditation, naturopathy, exercise, relaxation and deep breathing (Ivarsson *et al.*, 1998; Williamson *et al.*, 2002; Gorton, 1998; Chopin Luck, 2003; Younus *et al.*, 2003). The effect of nutritional supplements such as calcium on postmenopausal bone loss has also been explored (Aloia *et al.*, 1994). However, few studies have measured the use of CAMs in association with symptoms in menopausal women.

A number of studies have elucidated on the pharmacological action(s) of *Nigella sativa* (NS) seed extract or its active compound(s) on various body systems in vivo or in vitro. Conversely, among a long list of examples due to claimed usefulness in folk medicine; very few studies have reported the role of this versatile phytotherapeutic agent on the reproductive system.

Norton (1998) reported that *Nigella sativa* contains 23 different plant sterols. These sterols can fit onto the hormone receptors in the human body. This ability to fit onto the receptor sites may be useful in aging process particularly in relieving prostate inflammation and unpleasant menopausal symptoms. But, no data is available on the effects on female reproductive system, hormonal profile and unpleasant menopausal symptoms. Few studies that have reported its role in reproductive functions have focused on the male reproductive system. However, effect of *Nigella sativa* seeds on female reproductive functions remains largely unknown.

The studies on the effects of *Nigella sativa* on female reproductive system are very limited and almost all of them have focused on galactagogue effect or increasing milk production following *Nigella sativa* consumption. Furthermore, the subjects of all researches were normal animals and not ovariectomized (OVX) animals. The present study focuses on the other indices such as vaginal cytology, uterine changes such as uterine weight, uterine histology and metabolic status in response to *Nigella sativa* treatment in ovariectomized rats. Perhaps the same study in another experimental animal could address this issue. The findings may identify an effective and safe nutraceutical

product as food supplement which may be used to improve menopausal symptoms and metabolic changes after proving through necessitate researches on its efficacy and safety on other animal models. The purpose of the current study is to investigate the potential effect of *Nigella sativa* and some of its ingredients on the changes of menopausal characteristics of the ovariectomized rats as animal model of menopause. The menopausal characteristics included uterotrophic assay, uterine histological study, vaginal cytology, hormonal changes as well as metabolic status (Williamson and Okpako, 1996).

1.4 The use of rodents as an OVX model

The amount and types of research that can be conducted directly in women are extremely limited for ethical, practical, and financial reasons. Therefore, we must turn to animal models to shed light on the biology of menopause. Animal species that experience a similar menopausal process at a stage of their life history comparable to that in women presents an advantage because of the ability to utilize tighter control of genetic constitution and variation in experimental population and enable the researcher to perform invasive research under controlled experimental conditions. Whether a true animal model of human menopause exists will be clear only after extensive comparative studies were done. Nonhuman primate (NHP) species show substantial differences in reproductive and reproductive aging processes compared to humans, but some of these species, when ovariectomized, may provide appropriate models for postmenopausal health problems (Rodgers *et al.*, 1973; Thorndike and Turner, 1998; Bellino, 2000).

Nonhuman primates (NHPs) hold great promise, because some species appear to undergo a process very similar to what women experience across menopause. Thus, it may be useful to consider nonhuman primate animal species as potential models for pathophysiological changes associated with loss of reproductive function (Bellino, 2000). However, some important differences, such as substantially shorter postmenopausal life span and differences in the timing of hormonal changes during the menopausal transition appear to exist.

Currently there is no single animal model that identically represents the stages of menopause in humans as a whole (Thompson *et al.*, 1995), although there are some available models that provide a relatively close comparison. Both small animals and large animals are used depending on which aspects of the menopausal condition are being studied. Such animals include rats, rabbits, and sheep.

Of these animal models, the ovariectomised (OVX) rat model remains the most popular choice as it has been validated to represent the most important clinical features of estrogen deficiency-induced in the adult human (An and Friedman, 1998; Namkung-Matthai *et al.*, 2001). It also offers certain advantages compared to the other animal models like rabbits and sheep. These include cost effectiveness and ease of handling and housing (An and Friedman, 1998). Because of these considerations, the OVX rat model is widely used for studies associated with the prevention and treatment of symptoms associated with estrogen deficiency (Kalu, 1991; Namkung-Matthai *et al.*, 2001; Hoegh-Andersen *et al.*, 2004). The ovariectomized (OVX) rat is a widely used model to study estrogen withdrawal and replacement because many phenomena in this

rat model are similar to those occurring in postmenopausal women (Van Linden *et al.*, 2006). This method was used to analyze physiological, biochemical as well as histological effects induced in blood, uterus and vagina after short term (3 weeks) supplementation with oral administration of *Nigella sativa* crude powder, its different extracts and some of its ingredients in OVX rats and compared them with those treated by either Conjugated Equine estrogen (CEE) or control group.



1.5 Objectives

1.5.1 General objective

The objective of this study was to investigate the effects of *Nigella sativa* seeds, oil and its fractions supplementation on metabolic status and selected menopausal parameters of ovariectomized rat.

1.5.2 Specific objectives

1. To determine the effect of *Nigella sativa* seeds on metabolic status and selected menopausal parameters of OVX rats by measuring their weight gain, lipid profile (including TC, TG, LDL and HDL) and blood glucose; serum estradiol, uterine histological changes and vaginal smear (vaginal cornified cells, endometrial and myometrial diameters, endometrial glands, epithelial cell height and uterine luminal dilatation).
2. To determine the effect of *Nigella sativa* oil fractions obtained by solvent extraction and supercritical fluid extraction (SFE), on metabolic status and selected menopausal parameters of OVX rats by measuring the weight gain, lipid profile (including TC, TG, LDL and HDL), blood glucose; serum estradiol and vaginal smear (vaginal cornified cells).
3. To determine the effect of some fractions of *Nigella sativa* on metabolic status and selected menopausal parameters of OVX rats by measuring the weight gain,

lipid profile (including TC, TG, LDL and HDL), blood glucose ; the serum estradiol, and vaginal smear (vaginal cornified cells).

1.6 Research Hypothesis

- *Nigella sativa* seeds can improve selected menopausal parameters of OVX rats by increasing serum E2, vaginal cornified cells, endometrial and myometrial diameters, endometrial glands, epithelial cell height and uterine luminal dilatation.
- *Nigella sativa* seeds, oil and its fractions can improve metabolic status of OVX rats by decreasing serum glucose, triglyceride, total cholesterol, low density lipoprotein, weight and increasing high density lipoprotein.
- *Nigella sativa* oil and its fractions can improve selected menopausal parameters of OVX rats by increasing serum E2 and vaginal cornified cells.
- Selected ingredients of *Nigella sativa* have estrogen-like effects which improve selected menopausal parameters of OVX rats by increasing serum E2 and vaginal cornified cells.
- Selected ingredients of *Nigella sativa* have estrogen-like effects that improve metabolic status of OVX rats by decreasing serum glucose, triglyceride, total cholesterol, low density lipoprotein, weight and increasing high density lipoprotein.

REFERENCES

- AACE. (American Association of Clinical Endocrinologists). (2006). Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. *Endocr Pract.*, 12:315-37.
- AACE. (American Association of Clinical Endocrinologists). (1999). AACE medical guidelines for clinical practice for management of menopause. *Endocr. Pract.*, 5:355-366.
- ACOG. (American College of Obstetricians and Gynecologists Women's Health Care Physicians). (2004). Vasomotor symptoms. *Obstet Gynecol.*, 104(4 suppl): 106S-117S.
- ACOG (2004). Questions and answers on hormone therapy: In response to the Women's Health Initiative study results on estrogen and progestin hormone therapy. Available at <http://www.acog.org/> Accessed November 2, 2006.
- ACOG. (2001). Clinical Management. Guidelines for obstetrician- Gynecologists. Use of botanicals for management of menopause symptoms. *Obstet Gynecol.*, 97(6): 1-11.
- Adlercreutz, H. and Mazur, W. (1997). Phytoestrogens and western diseases. *Ann Med.* 29: 95-120.
- Agrawala, I.P., Achar, M.V.S. and Tamankar, B.P.(1971). Galactagogue action of *Nigella sativa*. *Ind J Med Sc.*, 25: 535-7.
- Agrawala, I.P., Acher, M.V.S., Boradker, R.V. and Roy, N. (1986). Galactagogue action of *Cuminum cyminum* and *Nigella sativa*. *Indian J Med Res.*, 56(6):841-844.
- Agrawal, C., Narula, A., Vyas, D.K., and Jacob, D. (1990). Effect of seeds of "Kalaunji" (*Nigella sativa*) on fertility and sialic acid content of the reproductive organs of the male rat. *Geobios*, 17: 269-272.
- Akhtar, M.S. and Riffat, S. (1991). Field trial of saussurea lappa roots against nematodes and *Nigella Sativa* seeds against cestodes in children. *J.Pakistan MED Assoc.*, 4:185-7.
- Al-Awadi, F.M., Khattar, M.A. and Gumaa, K.A. (1985). On the mechanism of the hypoglycemic effect of a plant extract. *Diabetologia*, 28:432-4.
- Al-Awadi, F.M. and Gumaa, K.A. (1987). Studies on the activity of individual plants of an antidiabetic plant mixture. *Acta Diabetol* , 24:7-41.

- Al-Awadi, F.M., Fatania, H. and Shamte, U. (1991). The effect of a plant mixture extract on liver gluconeogenesis in streptozotocin induced diabetic rats. *Diabetes Res.*, 18: 163-168.
- Albertazzi, P., Botazzi, M., Bonacorssi, G., Zanotti, L., Forini, E. and Aloysio, D. (1998). The effect of dietary soy supplementation on hot flashes. *Obstet gynecol.*, 91: 6-11.
- Albertazzi, P., Steel, S.A., Clifford, E. and Bottazzi, M. (2002). Attitudes towards and use of dietary supplementation in a sample of postmenopausal women. *Climacteric*, 5: 374-82.
- Albertazzi, P. (2005). Alternatives to estrogen to manage hot flushes, *Gynecol Endocrinol.*, 20:13-21.
- Albertazzi, P. and Sharma, S. (2005). Urogenital effects of selective estrogen receptor modulators: a systematic review. *Climacteric*, 8(3):214-220.
- Al-Ghadmi, M.S. (2001). Anti-inflammatory, analgesic and anti-pyretic activity of *Nigella Sativa*. *J. Ethnopharmacol* , 76:45-8.
- Al-Hader, A., Aqel, M. and Hasan, Z. (1993). Hypoglycemic effect of volatile oil of *Nigella Sativa* seeds. *Int. J. Pharmacog*, 31:96-100.
- Ali, A.B. and Ali, T.H. (2007). Beneficial Effects Of *Nigella Sativa* On The Testis Tissues Of Mice Exposed To UV Irradiation. *Research and Reviews in BioSciences*, 1(3).
- Ali, B.H. and Blunden, G. (2003). Pharmacological and toxicological peroperties of *Nigella Sativa*. *Journal of Phytotherapy Research*, 17(4):299-305.
- Al-Jassir, M.S. (1992). Chemical composition and microflora of Black Cumin (*Nigella Sativa* L.) seeds growing in Saudi Arabia. *J. Food Chemistry* , 45:239-242.
- Al-Jishi, S.A. and Abu Hozaifa B. (2002). Effect of *Nigella sativa* on blood hemostatic function in rats. *J. Ethnopharmacol*, 85:7-14.
- Al-Kubaisy, Kh. and Al-Noaemi, M. (2007). A Protective Role of *Nigella Sativa* Oil Against The Harmful Effect Of CCl₄ On The Liver Cells. *The Internet Journal of Nutrition and Wellness*, 3(1).
- Aloia, F., Vaswani A, Yeh K.J., Ross, P.L., Flaster, E. and Dilmanin, F.A. (1994). Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. *Annals of Internal Medicine*, 120(2), 97-103.

- Alsaif, M.A. (2008). Effect of *Nigella sativa* oil on impaired glucose tolerance and insulin insensitivity induced by high-fat-diet and turpentine induced-trauma. *Pakistan Journal of Biological Sciences*, 11(8):1093-1098.
- Amato, P. and Marcus, D.M. (2003). Review of alternative therapies for treatment of menopausal symptoms, *Climacteric*, 6: 278–284.
- An, Y.H. and Freidman, R.J. (1998). *Animal Models in Orthopaedic Research*. Boca Raton: CRC Press, 284.
- Anderson, I.M. (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. *Affect Disord.* 58:19-36.
- Anderson, G.L., Limacher, M., Assaf, A.R. and the Women's Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*. 291:1701–1712.
- Andrews, W.C. (1995). The transitional years and beyond. *Obstet Gynecol.*, 85(1):1-5.
- Anwar, M.A. (2005). *Nigella sativa*: A bibliometric study of the literature on Habbatul-Barakah. *Malaysian Journal of Library & Information Science*, 10(1): 1-18.
- Aqel, M., and Shaheen, R. (1996). Effect of the oil of *Nigella sativa* seed on the uterine smooth muscle of rat and guinea pig. *J Ethnopharmacol.*, 52 (1): 23-6.
- Araujo, L.B.F., Soares, J.M., Simoes, R.S. Ricardo Santos, S., Calió, P.L., Ricardo Oliveira-Filho, M., Simões, M.J., Haidar, M.A. and Baracat, E.C. (2006). Effect of conjugated equine estrogens and tamoxifen administration on thyroid gland histomorphology of the rat. *Clinics*, 61: 321-326.
- Arbonés-Mainar, J.M., Navarro, M.A. and Guzmán, M.A. (2006). Selective effect of conjugated linoleic acid isomers on atherosclerotic lesion development in apolipoprotein E knockout mice. *Atherosclerosis*, 189:318–27.
- Arici, M., Colak, F.A. and Gecgel, A. (2007). Effect of gamma radiation on microbiological and oil properties of black cumin (*Nigella sativa* L.). *Grasas Aceites*, 58 (4):339-343.
- Arjmandi, B. H., Birnbaum, R., Goyal, N. V., Getlinger, M. J., Juma, S., Alekel, L., Hasler, C. M., Drum, M. L., Hollis, B. W. and Kukreja, S. C. (1998). Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. *Am. J. Clin. Nutr.*, 68:1364S-1368S.

- Arsenault, B.J., Lemieux, I., Despre, J.P., Warehan, N.J., Luben, R., Kastelein, J.J.P., Khaw, K.T. and Boekholdt, S.M. (2007). Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. *European Heart Journal*. Advance Access published October 17, 2007. doi:10.1093/eurheartj/ehm390.
- Aryaeian, N., Shahram, F., Djalali, M., Eshragian, M.R., Djazayeri, A., Sarrafnejad, A., Naderi, N., Chamari, M., Fariha Fatehi, F. And Zarei, M. (2008). Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis. *Vascular Health and Risk Management*, 4(6);1423–1432.
- Asarian, L. and Geary, N. (2006). Modulation of appetite by gonadal steroid hormones. *Philos Trans R Soc Lond B Biol Sci.*, 361(1471):1251–1263.
- Asbury, E.A., Chandruangphen, P., and Collins, P. (2006). The importance of continued exercise participation in quality of life and psychological well-being in previously inactive postmenopausal women: a pilot study. *Menopause*, 13, 561-567.
- Ashby, J., Odum, J., Paton, D., Lefevre, P.A., Beresford, N. and Sumpter, J.P. (2000). Re-evaluation of the first synthetic estrogen, 1-keto-1,2,3,4-tetrahydrophenanthrene, and bisphenol A using both the ovariectomised rat model used in 1933 and additional assays. *Toxicology Letters*, 115: 231–238.
- Aso, T. (1997). Demography of the menopause and pattern of climacteric symptoms in the East Asian region, First Consensus Meeting on Menopause in the East Asian Region,. Geneva, 26 - 30 May 1997.
- Atta, M.B. (2003). Some characteristics of nigella (*Nigella Sativa* L.) seed cultivated in Egypt and its lipid profile. *J. Food Chemistry*, 83:63-68.
- Atul, N., Jadhav, K. and Bhutani, K. (2005). Ayurveda and gynecological disorders. *Journal of Ethnopharmacology*, 97:151–159.
- Aurand, L. W., Woods, A. E. and Wells, M. R. (1987). Food composition and analysis. Van Nostrand Reinhold Co., New York.
- Babayan, V. K., Koottungal, D. and Halaby, G. A. (1978). Proximate analysis, fatty acid and amino acid composition of *Nigella sativa* L. seeds. *J. Food Sci.*, 43: 1314-1319.
- Babiker, F. and Leon, J. (2002). Estrogenic hormone action in the heart: regulatory network and function. *Cardiovasc. Res.*, 53:709-719.

- Badary, O.A., Taha, R.A., Gamel El Din, A.M. and Abdel Wahab, M.H. (2002). The in vitro antioxidant and pro-oxidant action of thymoquinone and tert butylhydroquinone. *The Egypt J. Biochem. and Mol. Biol.*, 20: 1-16.
- Bachmann, G.A. (2004). Vasomotor flashes in menopausal women: a double-blind, randomized, placebo-controlled trial. *Am. J. Clin. Nutr.*, 79:326-333.
- Bachoric, P. (2000). Measurement of Low-Density Lipoprotein. 245-263. In: Handbook of Lipoprotein Testing (eds. Rifai, Warnick and Dominiczak), 2nd edition, AACC press, 2000.
- Balk, J.L., Whiteside, D.A., Naus, G., De Ferrari, E. and Roberts, J.M. (2002). A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. *Journal of Society for Gynecological Investigation*, 9: 238–242.
- Bamosa, A.O., Ali, B.A., Sawayan, S.A. (1997). Effect of oral ingestion of *Nigella Sativa* seed on some blood parameters. *J. Saudi Pharm.*, 5: 126-129.
- Banu, J., Bhattacharya, A., Rahman, M., O'Shea, M. and Fernandes, G. (2006). Effects of conjugated linoleic acid and exercise on bone mass in young male Balb/C mice. *Lipids in Health and Disease*, 23: 5-7.
- Barbieri, R.L., Lobo, R.A., Walsh, B.W. and Santoro, N.F. (2002). Improving quality of life during menopause: the role for hormone replacement therapy. In: APGO Educational Series on Women's Health Issues. p. 4–7.
- Barret-Connor, E. and Bush, T.L. (1991). Estrogen and coronary heart disease in women. *JAMA.*, 265:1861-1867.
- Barret-Connor, E. (1998). Hormone replacement therapy. *British Medical Journal (BMJ)*, 317:457-461.
- Barret-Connor, E. (2003). An epidemiologist looks at hormones and heart disease in women. *Journal of Clinical Endocrinology and Metabolism*, 88:4031-4042.
- Barton, D.L., Loprinzi, C.L., Quella, S.k., Sloan, J.A., Veeder, M.H., Egner, J.R., Fidler, P., Stella, P.J., Swan, D.K., Vaught, N.L., Novotny, P. (1998). Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. *J. Clin. Oncol.*, 16: 495-500.
- Basha, H.A. (1994). Response of two sesames cultivars to nitrogen level in newly reclaimed Sandy's oil. *J. Arric Res.*, 2:603-616.
- Bashandy, S. A. (2007). Effect of fixed oil of *Nigella sativa* on male fertility in normal and hyperlipidemic rats. *Inter. J. Pharmacol.*, 3 (1): 27-33.

- Belanger, C., Luu-The, V., Dupont, P. and Tchernof, A. (2002). Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. *Hormone and Metabolic Research*, 34 737–74.
- Bellino, F.L. (2000). Nonprimate animal models of menopause: workshop report. *Menopause*,7:14–24.
- Bellino, F.L. and Wise, P. M. (2003). Nonhuman Primate Models of Menopause Workshop. *Biology of Reproduction*, 68:10–18.
- Benny Braham, K., and Adithan, C. (2000). Review of endocrine pharmacology. *Indian J Pharmacol.*, 32:s67-s80.
- Beral, V. (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*, 362(9382):419–427.
- Bergstrom, S., Carlson, U A. and Weeks, J. R. (1968). The prostaglandins: A family of biologically active lipids. *Pharmacol Rev.*, 20: 201-210.
- Bhattacharya, A., Banu, J., Rahman, M. (2006). Biological effects of conjugated linoleic acids in health and disease. *J Nutr Biochem.*, 17:789–810.
- Bilal, A., Masud, T., Uppal, A. M. (2008). Black seed (*Nigella sativa*) regulates glucose, insulin level and lipid profile in patients with Type 2 diabetes. *Diabetes Research and Clinical Practice*,79(Supplement 1): S19-S20.
- Biskobing, D.M. (2003). Novel therapies for osteoporosis expert opine investing. *Drugs*, 12: 611-621.
- Bjarnason, N.H., Bjarnason, K., Haarbo, J., Coelingh Bennink H.J.T., Christiansen C. (1997). Tibolone: influence on markers of cardiovascular disease. *J. Clin. Endocrinol. Metab.*,82:1752-1756.
- Bjorntorp P. (1996). The regulation of adipose tissue distribution in humans. *Int J Obes Relat Metab Disord.*,20. 291 - 302.
- Bones, O. (2006). Menopause: What causes the menopause? Symptoms. Health risks. *Medical News Today* 17th July 2006.
- Bonnier, P., Romain, S., Giacalone, P.L., Laffargue, F., Martin, P.M. and Piana, L. (1995). Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. *Obstet Gynecol.*, 85(1):11-17.

- Boon, H., Brown, J.B., Gavin, A., Kennard, M.A. and Stewart, M. (1999). Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): making the decision to use or not to use, *Qual Health Res.*,9: 639–653.
- Boron, W. and Boulpaep, E. (2003). *Medical Physiology* Saunders, New York.
- Boronditsky, RS. (2000). Balancing safety and efficacy focus on endometrial protection. *J Reprod Med.*,45:273-84.
- Bose, K. (1996). Osteoporosis - A growing problem in South East Asia. *Medical Progress.* 1996 (May):5-7.
- Boskabady, M.H. and Farhadi, J. (2008). The Possible Prophylactic Effect of *Nigella sativa* Seed Aqueous Extract on Respiratory Symptoms and Pulmonary Function Tests on Chemical War Victims: A Randomized, Double-Blind, Placebo-Controlled Trial. *The Journal of Alternative and Complementary Medicine*, 14(9): 1137-1144.
- Boulet, M.J., oddens, B.J., Lehert, P., Vemer, H.M., Visser, A. (1994). Climacteric and menopause in seven South-East Asian Countries. *Maturitas*, 19:157-176.
- Bregman, R., Lemos, C.C.S., Caldas, M.L., and Gregório, S.M.P., (2002). Effect of dietary linoleic acid on the progression of chronic renal failure in rats. *Braz J Med Biol Res.*, 35(5); 573-579.
- Brett, K.M., and Madans, LH. (1997). Use of postmenopausal hormone replacement therapy: estimate from a nationally representative cohort study. *Am. J. Epidemiol.*, 145:536-545.
- Browngoehl, L.A. (2000). Osteoporosis. In: M. Giasois, J. Garrison, A.K. Hart and D.L. Lehmkuhl, Editors, *Physical Medicine and Rehabilitation*, Baylor Collage of Medicine, Houston, TX. pp. 1564–1575 [chapter 85] .
- Brown, M.S. and Goldstein, J.L., (1980). Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. *J. Lipid Res.*, 21: 505–517.
- Bruschi, F., Meschia, M., Soma, M., Perotti, D., Paoletti, R. and Crosignani, P.G. (1996). Lipoprotein (a) and other lipids after oophorectomy and estrogen replacement therapy. *Obstetrics and Gynaecology*, 88,950-954.
- Burger, H. (2002). Androgen production in women. *Fertility and Sterility*, 77(4):3-5.
- Burger, H. (2003). Hormone replacement therapy in the post- Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24–25, 2003. *Climacteric*,6(suppl 1):11–36.

- Burghardt, M. (1999). Exercise at menopause: a critical difference. *Medscape Womens Health*, 4(1):1.
- Buriro, M.A. and Tayyab, M. (2007). Effect of *Nigella sativa* on Lipid Profile in Albino Rats. *Gomal Journal of Medical Sciences*, 5(1):28-31.
- Bush, T.L. (1987). Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. *Circulation*, 75:1102 – 1109.
- Bush, T.L. and Whiteman, M.K. (1999). Hormone replacement therapy and risk of breast cancer. *Editorial Journal of the American Medical Association*, 281(22):2140-2141.
- Bush, T.L. (2006). The Epidemiology of Cardiovascular Disease in Postmenopausal Women. *Annals of the New York Academy of Sciences*, 592 (1):263 – 271.
- Cardozo, L., Buchman, G., McClish, D., Fonda, D., Birgerson, L. (1998). Meta-Analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. *Obstet Gynecol.*, 92:722-728.
- Carr, M.C. (2003). The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab.*, 88:2404-2411.
- Carranza-Lira, S., Cortes-Fuentes, E. (2001). Modification of vasomotor symptoms after various treatment modalities in the postmenopause. *Int J Gynaecol Obstet.*, 73: 169-171.
- Cassidy, A., Bingham, S. and Setchell, K.D.R. (1994). Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. *Am. J. Clin. Nutr.*, 60: 333–340.
- Cauley, J.A., Robbins, J., Chen, Z., Cummings, S.R., Jackson, R.D., Lacroix, A.Z., LeBoff, M., Lewis, C.E., McGowan, J., Neuner, J., Pettinger, M., Stefanick, M.L., Wastawski-Wende, J. and Watts, N.B. (2003). Effect of estrogen plus progestin on risk of fractures and bone mineral density. The Woman's health Initiative randomized trial. *JAMA.*, 290:1729-1738.
- Chang, C. J., Wu, C.H., Yao, W. J., Yang, Y.C., Wu, J.S. and Lu, F.H. (2000). Relationships of age, menopause and central obesity on cardiovascular disease risk factors in Chinese women. *International Journal of Obesity*, 24, 1699-1704.

- Cheikh-Rouhou, S., Besbes, S., Lognay, G., Blecker, C., Deroanne, C. and Attia, H. (2008). Sterol composition of black cumin (*Nigella sativa* L.) and Aleppo pine (*Pinus halepensis* Mill.) seed oils. *Journal of Food Composition and Analysis*. 21; 162–168.
- Chenoy, R., Hussain, S., Tayob, Y., O'brien, P.M., Moss, M.Y. and Morse, P.F. (1994). Effect of oral gamolenic and from evening primrose oil on menopausal flushing. *British Medical Journal*, 308, 501-503.
- Chetkowski, R.J., Meldrum, D.R., Steingold, K.A. (1986). Biologic effects of transdermal estradiol. *N. Engl. J. Med.*, 314:1615-20.
- Chiechi, L.M., Putignano, G., Guerra, V., Schiavelli, M.P., Cisternino, A.M. and Carriero, C. (2003). The effect of a soy rich diet on the vaginal epithelium in post menopause: a randomized double blind trial. *Maturitas*, 45: 241–246.
- Chima, H., Tana, B.H., Anga, C.C., Darryl Chewa, E.M., Chongb, Y.S. and Saw, S.M. (2002). The prevalence of menopausal symptoms in a community in Singapore. *Maturitas*, 21: 275–82.
- Choi, M.W. (1995). The menopause transition: change, loss, and adaptation. *Holist Nurse Pract.* 3:53-62.
- Chopin Lucks, B. (2003). Vitex agnus castus essential oil and menopausal balance a research update, *Complementary Therapies in Nursing and Midwifery*, 9, 157-160.
- Coad, J. and Dunstall, M. (2005). *Anatomy and Physiology for Midwives*. Second Edition.
- Colditz, G.A. (1997). Estrogen replacement therapy for breast cancer patients. *Oncology* 11:1491-1497.
- Collaborative group on hormonal factors in breast cancer. (2003). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. *Lancet*, 350:1047-1059.
- Contreras, I. and Parra, D. (2000). Estrogen Replacement Therapy and the Prevention of Coronary Heart Disease in Postmenopausal Women. *Am J Health-Syst Pharm.*, 57(21):1963-1971.
- Cook, J.W., Dodds, E.C., Hewett, C.J. (1933). A synthetic oestrus-exciting compound. *Nature*, 131:56–57.

- Couse, J.F. and Korach, K.S. (1999). Estrogen receptor null mice: what have we learned and where will they lead us? *Endocr Rev.*, 20(3):358-417.
- Cramer, D.W., Harlow, B.L., Xu, H., Fraer, C. and Barbieri, R. (1995). Cross-sectional and case-control analyses of the association between smoking and early menopause. *Maturitas*, 22(2), 79-87.
- Cushman, M., Kuller, L.H., Prentice, R. (2004). Estrogen plus progestin and risk of venous thrombosis. *JAMA.*, 292:1573-80.
- Damoran, P., Subramaniam, R., Omar, S.Z. (2000). Profile of a Menopause Clinic in an Urban Population in Malaysia. *Sing Med J.*, 431-435:41.
- Dandik, L., Aksoy, H.A. (1992). The kinetics of hydrolysis of *Nigella sativa* (Black cumin) seed oil catalyzed by native lipase in ground seed. *J Am Oil Chem Society.*, 69(12): 1239-1241
- Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumly, A., Low, G.D.O., Pepys, M.B. and Gudnason, V. (2004). C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med.*, 350:1387-1397.
- Davidson, N.E. (1996). Is hormone replacement therapy a risk? *Scientific American*, 273(3):101.
- Davis, S.R. (2001). Phytoestrogen therapy for menopausal symptoms? There's no good evidence that it's any better than placebo. *BMJ.*, 323: 354-355.
- Deliconstantinos, G. and Ramantnis, G. (1982). Evoked effects of oestradiol on hepatic cholesterol 7 alpha-hydroxylase and drug oxidase in castrated rats. *The International Journal of Biochemistry*, 14(9):811-815.
- Deligdisch, L. (2000). Hormonal pathology of the endometrium. *Modern Pathology*, 13:285-294.
- Dennerestien, L., Smith, A.M.A., Morse, C., Burger, H., Green, A., Hopper, J. and Ryan, M. (1993). Menopausal symptoms in Australian Women. *Medical journal of Australia*, 159:232-236.
- Department of Statistics, Malaysia. (1998). *Senior Citizens and Population Ageing in Malaysia*. Population Census Monograph Series no. 4. Kuala Lumpur: National Printing Department.
- Desroches, S., Chouinard, P.Y., Galibois, I. (2005). Lack of effect of dietary conjugated linoleic acids naturally incorporated into butter on the blood lipid profile and body composition of overweight and obese men. *Am J Clin Nutr*, 82:309-19.

- Dhillon, H.K., Singh, H.J., Shuib, R., Hamid, A.M., Mahmood, N. and Mohd. Z.N. (2006). Prevalence of menopausal symptoms in women in Kelantan, Malaysia. *Maturitas*, 54(3): 213-221.
- Diel, P., Schulz, T., Smolnikar, K., Strunck, E., Vollmer, G. and Michna, H. (2000). Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rats uterus: estrogenicity profiles and uterotrophic activity. *Journal of Steroid Biochemistry and Molecular Biology*, 73: 1–10.
- Dieudonne, M.N., Sammari, A., Dos Santos, E., Leneveu, M.C., Giudicelli, Y. and Pecquery, R. (2006). Sex steroids and leptin regulate 11beta-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: sex specificities. *Journal of Steroid Biochemistry and Molecular Biology*, 99 189–196.
- Disseldorp, J. V., Faddy, M.J., Themmen, A.P., Jong, F.H., Peeters, P.H., Schouw, Y.T., Broekmans, F.J. (2008). Relationship of serum antimullerian hormone concentration to age at menopause. *J. Clin. Endocrinol. Metab.*, 93:2129–2134.
- Dorgan, J.F., Reichman, M.E., Judd, J.T., Brown, C., Longcope, C., Schatzkin, A., Forman, M., Campbell, W.S., Franz, C. and Kahle, L. (1996). Relation of energy, fat, and fiber intakes to plasma concentrations of estrogens and androgens in premenopausal women. *American Journal of Clinical Nutrition*, 64:25–31.
- Dorgan, J.F., Hunsberger, S.A., McMahon, R.P., Kwiterovich, P.J., Lauer, R.M., Van Horn, L., Lasser, N.L., Stevens, V.J., Friedman, L.A. and Yanovski, J.A. (2003). Diet and sex hormones in girls: findings from a randomized controlled clinical trial. *Journal of the National Cancer Institute*, 95:132–145.
- Dormire, Sh. And Howharn, Ch. (2007). The Effect of Dietary Intake on Hot Flashes in Menopausal Women. *Journal of Obstetric, Gynecologic and Neonatal Nursing*, 36(3); 255 – 262.
- Drapier Faure, E., Chantre, P. and Mares, P. (2002). Effects of a standardized soy extract on hot flashes a multi center, Double-blind, randomized, placebo-controlled study. *Menopause*, 9(5), 329-334.
- Duker, E., Kopanski L., Jarry H. and Wuttke W., (1991). Effects of extracts from cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. *Planta Medicina*, 57:420-424.
- Dunn, A.L., Trivedi, M.H., and O'Neal, H.A. (2001) Physical activity dose-response effects on outcomes of depression and anxiety. *MSSE*, 33, 587-597.
- Eisenberg, D.M., Kessler R.C. and Van Rompay, M.I. (2001). Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. *Ann. Intern. Med.*, 135:344–351.

- Elavsky, S., and McAuley, E. (2007). Physical activity and mental health outcomes during menopause: A randomized controlled trial. *Ann Behav Med.*, 33, 132-142.
- El-Dakhakhny, M., Barakat, M. And El-Halim, M.A. (2000). Effect of *Nigella Sativa* oil on gastric secretion and ethmol-induced ulcer in rats. *J. Ethnopharmacol.*,72:299-304.
- El Dakhakhny, M., Mady, N.L., Halim, M.A. (2000). *Nigella sativa* L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. *Arzneimittelforschung*, 50(9); 832-6.
- El-Dhaw, Z.Y. and Abdel-Munaem, N.M. (1996). Chemical and biological values of black cumin seeds. *J. Agric. Sci. Mansoura Univ.*, 21:4149–4159.
- Elkind-Hirsch, K. (2001). Effect of dietary phytoestrogens on hot flushes: can soy based proteins substitute for traditional estrogen replacement therapy? *Menopause*, 8 (3): 154–156.
- El-Naggar, A.R.M. and El-Deib, A.E.M. (1992). A study of some biological activities of *Nigella sativa* (black seeds) “Habbat El-Barka”. *J Egypt Soc Pharmacol Exp Ther.*, 11 (2): 781-800.
- El-Shabrawy, O.A., and Nada, S.A. (1996). Biological evaluation of multicomponent tea used as hypoglycemic in rats. *Fitoterapia*, 15(2):99-102.
- El-Tahir, K.E.K., Ashour, M.M.S. and Al-Harbi, M.M., (1993). The cardiovascular actions of the volatile oil of the black seed *Nigella sativa* in rats: elucidation of the mechanism of action. *General Pharmacology*, 24 (5);1123–1131.
- El-Tahir, K.E., Al-Tahir, A.Y. and Ageel, A.M. (1999). Pharmacological studies on sesame and *Nigella sativa* fixed oils: Effects on the sensitivities of the adrenoceptors, baroreceptors, platelets and the uterus of the rat. *Saudi Pharmaceutical J.*, 7 (4): 205-15.
- Emanuele, M., Wezeman, F., and Emanuele, N.V. (2002). Alcohol’s effects on female reproductive function. *Alcohol Research and Health*, 26(4):274-281.
- Enomoto, S., Asano, R., Iwahori, Y. (2001). Hematological studies on black cumin oil from the seeds of *Nigella sativa* L. *Boil. pharm Bull.*, 24, 307-310.
- Eskander, H., Emad, F., Won Jun, A., Ibrahim, K. and Abelal, W.E. (1995). Hypoglycemic effect of a herbal formulation in alloxan-induced diabetic rats. *Egypt J Pharm Sci.*, 36:253-70.

- Eviö, S., Tlitinen, A., Laitinen, K., Ylikorkala, O., and Välimäki, M.J. (2004). Effect of alendronate and hormone replacement therapy, alone and combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. *J Clin Endocrinol Metab.*, 89:626-631.
- Fait, T., Malkova, J., and Zivny, J. (2002). Effect of hormone replacement therapy on the cardiovascular system. *Ceska. Gynecol.*, 67 (5):285–293.
- Fararh, K. M., Atoji, Y., Shimizu, Y. and Takewaki, T. (2002). Isulinotropic properties of *Nigella sativa* oil in Streptozotocin plus Nicotinamide diabetic hamster . *Research in Veterinary Sciences*, 73(3): 279-282.
- Fararh, K.M., Atoji, Y., Shimizu, Y., Shiina, T., Nikami, H. and Takewaki, T. (2004). Mechanisms of the hypoglycaemic and immuopotentiating effects of *Nigella sativa* L. oil in streptozotocin-induced diabetic hamsters. *Res Vet Sci.*, 77: 123-129.
- Fernandez-Twinn, D.S., Ozanne, S.E., Ekizoglou, S., Doherty, C., James, L., Gusterson, B. and Hales, C.N. (2003). The maternal endocrine environment in the low-protein model of intra-uterine growth restriction. *British Journal of Nutrition*, 90:815–822.
- Felicio, L.S., Nelson, J.F., Gosdo.G., Finch, C.E. (1983). Restoration of ovulatory cycles by young ovarian grafts in aging mice: potentiation by long-term ovariectomy decreases with age. *Proc. Natl. Acad. Sci., USA.*, 80: 6076-6080.
- Finch, CE., Felicio, LS, and Nelson, JF. (1984). Longitudinal studies of estrous cyclicity in ageing C57BL/6J mice. II. Cessation of cyclicity and the duration of persistent vaginal cornification. *Biol Reprod.*, 31, 446-53.
- Flecknell, P. (1996). *Laboratory Animal Anesthesia*, 2nd Edition, Academic Press, San Diego.
- Fogle, R.H., Stanczyk, F.Z., Zhang, X. (2007). Ovarian Androgen Production in Postmenopausal Women. *J. Clin. Endocrinol. Metab.* 92:3040-3043.
- Folch, J., Lees, M. and Sloan-Stanley, G.H. (1957). A simple method for the isolation and purification of Total Lipids from Animal tissues. *Journal of Biological Chemistry*, 226:497-509.
- Freeman, M.E. (1988). The ovarian cycle of the rat. In: E. Knobil and J.D. Neill.Editors, *The Physiology of Reproduction*.Raven Press Ltd., New York. pp. 1893–1928.
- Friedwald, W.T., Levy, R.I. and Fredrickson, D.S. (1972). Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. *Clin Chem.*, 18: 499.

- Fournier, A., Berrino, F., Riboli, E., Avenel, V. and Clavel-Chapelon, F. (2005). Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer*,114: 448–454.
- Fukami, K., Koike, K., Hirota, K., Yoshikawa, H. and Miyake, A. (1995). Perimenopausal changes in serum lipids and lipoproteins: A 7-year study. *Maturitas*, 22:193-197.
- Fuh, J., Wang, S.J/, Lu, S.R., Juang, K.D., Chiu, L.M. (2001). The Kinmen Women-health investigation (KIWI): a menopausal study of a population aged 40–54. *Maturitas*, 39:117–24.
- Gavino, V.C., Gavino, G., Leblanc, M.J. (2000). An isomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11-octadecadienoic acid affects body weight gain and plasma lipids in hamsters. *J Nutr.*, 130:27–9.
- Gannon, L. and Stevens, J. (1998). Portraits of menopause in the mass media, *Women Health*, 27:1–15.
- Gaspard, U.J., Gottal, J.M., and Vander Brule, F.A. (1995). Postmenopausal changes of lipid and glucose metabolism: A review of their main aspects. *Maturitas*, 21:171-178.
- Gass, M.L.S., and Taylor M.B. (2001). Alternatives for women through menopause. *AMJ Obstet Gynaecol.*,185: 47-56.
- Genazzani, A. R., Stomati, M., Bernardi, F.,Luisi S., Casarosa, E., Puccetti, S., Genazzani, A.D., Palumbo, M. and Luisi, M. (2004). Conjugated equine estrogens reverse the effects of aging on central and peripheral allopregnanolone and beta-endorphin levels in female rats. *Fertility and Sterility*, 81(1): 757-766.
- Ginsburg, J., Prelevic, G.M. (2000). Lack of significant hormonal effects and controlled trials of phytoestrogens. *Lancet*,355: 163-164.
- Ghanya, N. A. N., (2005). Nutrient composition and hypocholesterolemic effect of Black Seeds (*Nigella sativa L.*) and its oil. Unpublished Master Dissertation, Universiti Putra Malaysia.
- Ghosheh, O.A., Houdi, A.A., and Crooks, P.A. (1999). High performance liquid chromatographic analysis of the pharmacologically active quinines and related compounds in the oil of Black Seed (*Nigella Sativa L.*) *J. Pharm. Biomed Anal.*, 5:757-62.
- Glazier, M.G. andBowman, M.A. (2001). A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy, *Arch Intern Med.*, 161:161–1172.

- Gold, E.B., Colvin, A., Avis, N., Bromberger, J., Greendale, G. A. Powell, L., Sternfeld, B., and Matthews, K. (2006). Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. *Am. J. Public Health*, 96:1226-35.
- Goldberg, R.M., Loprinzi, C.L., O'Fallon, J.R., Veeder, M.H., Miser, A.W., Milliard, J.A., Michalak, J.C., Dose, A.M., Rowland, K.M.J. and Burnham, N.L. (1994). Transdermal clonidine for ameliorating tamoxifen induced hot flashes. *J. Clin. Oncol.*, 12:155-158.
- Goldstein, MS., Glik, D. (1998). Use of and satisfaction with homeopathy in a patient population. *Altern Ther Health Med.*, 4:60-5.
- Gorodeski, G.I. (2002). Update on cardiovascular disease in post-menopausal women. *Clinical Obstetric and Gynecology*, 16(3): 329-355.
- Gorton, D. (1998). Holistic health techniques to increase individual coping and wellness. *Journal of Holistic Nursing*, 6(1), 25-30.
- Grady, D. (2002). Effect of postmenopausal hormonal therapy on cognitive function: the hormone therapy and estrogen/progesterone replacement study. *Amer J Med.*, 113:543-8.
- Grady, D. (2006). Management of Menopausal Symptoms. *NEJM.*, 355 (22):2338-2347.
- Grady, D., Rubin, S. M. Petitti, D.B., Fox, C.S., Black, D., Ettinger, B., Ernster, V.L. and Cummings, S.R. (1992).Hormone Therapy to Prevent Disease and Prolong Life in Postmenopausal Women. *Archives of Internal Medicine*, 117 (12): 1016-1037.
- Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., Newby, LK., Waters, D., Vittinghoff, E. and Wenger, N., for the HERS Research Group. (2002). Cardiovascular disease outcome during 6.8 years of hormone therapy. Heart and Estrogen/ progestin replacement study follow up (HERSII). *JAMA.*, 288:49-57.
- Greenland, P., Knoll, M.D., Stamler, J., Neaton, J.D., Dyer, A.R., Garside, D.B. and Wilson, P.W. (2003). Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. *JAMA.*, 290:891-897.
- Greendale, G.A., Lee, N.P., Arriola, E.R. (1999). The menopause. *Lancet*, 353:571-580.
- Greeves, J.P., Cable, N.I., Reilly, T. T. and Kingsland, C. (1999). Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy. *Clinical Science*,(1999) 97, 79-84.

- Greiling, H., Gressner, A.M. (1995). Lehrbuch der Klinischen Chemie Und pathobiochemie, 3rd ed. Stuttgart/New York: Schattauer Verlag.
- Grodstein, F., Stampfer, M.J., Manson, J.E., Colditz, G.A., Willett, W.C., Rosner, B., Speizer, F.E. and Hennekens, C.H. (1996). Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *New England Journal of Medicine*, 335:453-461.
- Grodstien, F., Manson, J.E., Colditz, G.A., Willett, W.C., Speizer, F.E. and Stampfer, M.J. (2000). A prospective observational study of post menopausal hormone replacement therapy and primary prevention of cardiovascular disease. *Ann Intern Med.*,133:933-941.
- Gruber, C.J., Tschugguel, W., Schneeberger, C. and Huber, J.C. (2002). Production and actions of estrogens. *N. Engl. J. Med.*, 346:340-352.
- Gunin, A.G., Mashin, I. N. and Zakharov, D. A. (2001). Proliferation, mitosis orientation and morphogenetic changes in the uterus of mice following chronic treatment with both estrogen and glucocorticoid hormones. *Journal of Endocrinology*. 169:23–31
- Haddad, P.S., Martineau, L., Lyoussi, B. and Le, P.M. (2006) Middle Eastern and African medicine. In: A. Soumyanath, Editor, *In Traditional Herbal Medicines for Modern Times: Antidiabetic Plants*, CRC Press, Boca Raton, FL, pp. 221–241.
- Hafanizam, M.B.H., Dollah, M.A., Latiff, A.L. and Rahman, S.A. (2008). Toxicity effects of *Nigella sativa* supplementation on the liver function of rats. Universiti Putra Malaysia, Unpublished Thesis.
- Hajdu, A., Chappel, C. I. and Rona, G. (1965). The influence of estrogens on scorbutic bone lesions in guinea-pigs. *CMLS*, 21(8): 466-467.
- Hanachi, p. and Golkho, Sh. (2008). Assessment of Soy phytoestrogens and exercise on lipid profile and menopause symptoms in menopausal women. *Journal of Biological Sciences*, 7(4):789- 793.
- Hanafy, M.S. and Hatem, M.E. (1991). Studies on the anti-microbial activity of the *Nigella Sativa* seed (Black Cumin). *J. Ethnopharmacol.*, 34: 275-278.
- Hanretty, K.P. (2003). *Obstetrics Illustrated*. 6th Edition. Elsevier , Churchill Livingstone. Philadelphia, USA.
- Haq, A., Lobo, P.L., Al-Tufail, M., Rama, N.R. and Al-Sedairy, S. (1995). Immunomodulatory effect of *Nigella Sativa* proteins fractionated by ion exchange chromatography. *J. Immunopharmacol.*, 21:283-5.

- Harbers, M.M. (RIVM) (2008).  Old-age dependency ratio, trend and projections, in selected countries, 1950-2050. Available at: <http://www.euphix.org>. Accessed May 22 , 2008.
- Hardy, M. (2000). Herbs of special interest to women. *J Am Pharm Assoc.*, 40 (2): 234–242.
- Harris, W.S., Connor, W.E. and McMurry, M.P. (1983). The comparative reductions of the plasma lipids and lipoproteins by dietary polyunsaturated fats: Salmon oil versus vegetable oils. *Metabolism*, 32: 179-184.
- Hassanzadeh Ghahramanloo, K., Latiffah, A.L., Mirhosseini, H., Hanachi, P. and Nordin, H.J. Lajis. (2008). Comparative analysis of essential oil composition of Iranian and Indian *Nigella sativa* extracted by using Supercritical Fluid Extraction (SFE) and solvent extraction. *Phytochemistry*, [In Press]
- Hawsawi, Z.A., Ali, B.A., Bamosa, A.O. (2001). Effect of *Nigella sativa* (Black seed) and thymoquinone on blood glucose in Albino rats. *Annals of Saudi Medicine*, 21(3-4), 242-244.
- Hedaya, S.A. (1995). Effect of *Nigella sativa* seeds (black seeds) extract on some hematologica and biochemical parameters in rats. *Alexandria J Vet Sci.*, 11(2): 95-99.
- Heinemann, C. and Reid, G. (2005). Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. *Can J Microbiol.*, 51(9):777–781.
- Henry, L. A. and Witt, D. M. (2002). Resveratrol: Phytoestrogen Effects on Reproductive Physiology and Behavior in Female Rats. *Horm Behav.*, 41(2): 220-228.
- Hernández-Ceruelos, A., Madrigal-Bujaidar, E. and de la Cruz, C. (2002). Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methyl methanesulfonate in mouse bone marrow. *Toxicology letters*, 135(1-2):103-110.
- Heyerick, A., A., Vervarcke, S., Depypere, H., Bracke, M. And De Keukeleire, D. (2006). A first prospective, randomized, double-blind, placebo-controlled study on the use of standardized hop extract to alleviate menopausal discomfort. *Maturitas*, 54: 164-175.
- Heymsfield, S.B., Gallagher, D., Poehlman, E.T., Wolper, C., Nonas, K., Selson, D. and Wang, Z.M. (1994). Menopausal changes in body composition and energy expenditure. *Exp. Gerontol.*, 29: 377-389.

- Hilakivi-Clarke, L., Cho, E. and Onojafe, I. (1996). High-fat diet induces aggressive behavior in male mice and rats. *Life Science*,58:1653–1660.
- Hilakivi-Clarke, L., Clarke, R., Onojafe, I., Raygada, M., Cho, E. and Lippman, M.(1997). A maternal diet high in n-6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring. *PNAS*, 94:9372–9377.
- Hilakivi-Clarke, L., Cho, E., Cabanes, A., DeAssis, S., Olivo, S., Helferich, W., Lippman, M.E, and Clarke, R. (2002). Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. *Clinical Cancer Research*,8:3601–3610.
- Hines, L.M., Rimm, E.B. (2001). Moderate alcohol consumption and coronary heart disease: a review. *Postgrad. Med. J.*, 77:747-752.
- Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. (1997). Does dong quai have estrogenic effect in postmenopausal women? A double- blind, placebo-controlled trial. *Fertility and Sterility*, 68(6), 981-986.
- Ho, S.C, Chan, S.G, Yip, Y.B, Cheng, A, Yi, Q., Chan, C. (1999). Menopausal symptoms and symptoms clustering in Chinese women. *Maturitas*, 33:219-227.
- Hoegh-Andersen, p., Tanko, L.B., Andersen, T.L., Lundberg, C.V., John A Mo, J.A., Heegaard, A.M., Delaisse, J.M. and Christgau, S. (2004). Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. *Arthritis Res Ther.*, 6:R169-R180.
- Hostmark, A.T., Spydevold, O., Lystad, E. (1989). Plasma high density lipoprotein subgroup distribution in rats fed diets with varying amounts of sucrose and sunflower oil. *Lipid*, 17: 489-99.
- Holmberg, L., and Anderson, H. (2004). For the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomized comparison: trial stopped. *Lancet*,363:453-455.
- Houcher, Z., Boudiaf, Kh., Benboubetra, M. and Houcher, B. (2007). Effects of Methanolic Extract and Commercial Oil of *Nigella sativa* L. on Blood Glucose and Antioxidant Capacity in Alloxan-Induced Diabetic Rats. *Pteridines*,18:8-18.
- Houghton, P.J., Zarka, R., Heras, B. and Hoult, J.R. (1995). Fixed oil of *Nigella sativa* and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. *Planta Med.*,61: 33-36.

- Howard, B.V., Van Horn, L., Hsia, J., Manson, J.E., Stefanick, M.L., Wassertheil-Smoller, S., Kuller, L.H., LaCroix, A.Z., Langer, R.D., Lasser, N.L., Lewis, C.E., Limacher, M.C., Margolis, K.L., Mysiw, W.J., Ockene, J.K., Parker, L.M., Perri, M.G., Phillips, L., Prentice, R.L., Robbins, J., Rossouw, J.E., Sarto, G.E., Schatz, I.J., Snetselaar, L.G., Stevens, V.J., Tinker, L.F., Trevisan, M., Vitolins, M.Z., Anderson, G.L. and Assaf, A.R. (2006). Low fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA.*, 295:655-666.
- Huang, H.H. and Mietes, J. (1975). Reproductive capacity of aging female rats. *Neuroendocrinology*, 17; 289-295.
- Hu, Y., Hou, T.T., Xin, H.L., Zhang, Q.Y., Zheng, H. C., Rahman, Kh. and Qin, L.P. (2007). Estrogen-like activity of volatile components from *Vitex rotundifolia* L. *Indian J Med Res.*, 126, 68-72.
- Huntley, A.L. and Ernst, E. A. (2003). Systematic review of herbal medicinal products for the treatment of menopausal symptoms, *Menopause*, 10:465–476.
- Huntley, A.L. and Ernst, E. A. (2004). Soy for the treatment of perimenopausal symptoms: a systematic review, *Maturitas*, 47:1–9.
- Ingkaninan, K., von Frijtag Drabbe Kunzel JK, IJzerman AP, Verpoorte R (1999) Interference of linoleic acid fraction in some receptor binding assays. *J. Nat Prod.*, 62: 912–914.
- Intan, N.F.S., Rashid, I., Abdul Latif, L. and Dollah, M.A. (2007). Effect of Short-term Supplementation of *Nigella savita* on Oestrogen Level in Ovarietomised Rabbits. 2nd Proceeding of the Seminar on Veterinary Sciences. 15-19 January 2007. 132-135.
- Intan, N.F.S., Rashid, I., Abdul Latif, L. and Dollah, M.A. (2008). Effect of Short-term Supplementation of *Nigella savita* on Oestrogen Level in Ovarietomised Rabbits. Universiti Putra Malaysia, Unpublished Thesis.
- Inuwa, I. and Williams, M.A. (1996). Morphometric study on the uterine horn and thyroid gland in hypothyroid, and thyroxine-treated hypothyroid rats. *J. Anat.* 188, pp. 383–393.
- Isles, C.G., Hole, D.G., Hawthorne, V.M. and Lever, A.F. (1992). Relation between coronary risk and coronary mortality in women of the Renfrew and paisley Survey: Comparison with men. *Lancet*, 339:702-706.

- Ishida, H., Uesugi, T., Hirai, K., Toda, T., Nukaya, H., Yokotsuka, K. and Tsuji, K. (1998). Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet. *Biol. Pharm. Bull.*, 21:62-66.
- Ivarsson, T., Spetz, A. and Hammer, M. (1998). Physical exercise and vasomotor symptoms in postmenopausal women. *Maturitas*, 29(2), 139-146.
- Izwan, M.E.M., Dollah, M.A., Latiff, A.L. and Rahman, S.A. (2008). Toxicity effects of *Nigella sativa* supplementation on the kidney function of rats. Universiti Putra Malaysia, Unpublished Thesis.
- Jahanfar, Sh., Abdul Rahim, B. A., Shah Reza, B. K., Nor Azura, B.I., Sharifah Nora, B. S. A. D. and Siti Asma, B. A. R. (2006). Age of Menopause and Menopausal Symptoms among Malaysian Women, who referred to Health Clinic in Malaysia. *Shiraz E-Medical Journal*, 7(3).
- Johnson, M.H. and Everitt, B.J. (1995). *Essential Reproduction*. Blackwell Science, London. pp. 79–108.
- Johnson, S.R. (1998). Menopause and hormone replacement therapy. *Med. Clin. North Am.*, 82:297-320.
- Jones, M.L., Eichenwald, T. (2007). *Menopause for Dummies*, 2nd edition. Wiley Publishing Inc., Indianapolis, Indiana, USA.
- Juarbe, T.C., Gutiérrez, Y., Gilliss, C. and Lee, K.A. (2006). Depressive symptoms, physical activity, and weight gain in premenopausal Latina and white women. *Maturitas*, 55, 116-125.
- Jung, B.H., Jeon, M.J. and Bai, S.W. (2008). Hormone-Dependent Aging Problems in Women. *Yonsei Med. J.*, 49(3):345 – 351.
- Kabir, K.K., Varshney, J.P., Rawal, C.V.S., Srivastava R.S. and Ansari, M.R. (2001). Comparative efficacy of herbal preparation in the management of anoestrus in non-descript rural buffnaaloes. *Indian Journal Animal Reproduction*, 22: 143-145.
- Kaku, S., Ohkura, K., Yunoki, S., Nonaka, M., Tachibana, H., Sugano, M. and Yamada, K. (2001). Dietary gamma-linolenic acid dose-dependently modifies fatty acid composition and immune parameters in rats. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 65(4); 205-210.
- Kalu, D.N. (1991). The ovariectomized rat model of postmenopausal bone loss. *Bone Miner.*, 15(3):175-191.

- Kang, J.X., and Leaf, A. (1994). Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. *Proc Natl Acad Sci U.S.A.*, 91: 9886–9890.
- Kanis, J.A., Melton, L.J., Christiansen, C., Johnston, C.C. and Khaltsev, N. (1994). The diagnosis of osteoporosis. *J Bone Miner Res.*, 9:1137-1141.
- Kanno, J., Onyon, L., Haseman, J., Fenner-Crisp, P., Ashby, J. and Owens, W. (2001). The OECD program to validate the rat uterotrophic bioassay to screen compounds for *in vivo* estrogenic responses: Phase 1. *Environ Health Perspect.*, 109:785-794.
- Kanter, M., Meral, I., Yener, Z., Ozbek, H. and Demir, H. (2003). Partial regeneration/proliferation of the beta-cells in the islets of Langerhans by *Nigella sativa* L. in streptozotocin-induced diabetic rats. *Tohoku J Exp Med.*, 201: 213-219.
- Kanter, M., Coskun, O., Korkmaz, A. and Oter, S. (2004). Effects of *Nigella sativa* on oxidative stress and beta-cell damage in streptozotocin-induced diabetic rats. *Anat Rec A Discov Mol Cell Evol Biol.*, 279: 685–691.
- Kass-Annese, B. (2000). Alternative therapies for menopause. *Clinical Obstetrics and Gynecology*, 43 (1), 162-183.
- Kato, J. (1989). Arachidonic acid as a possible modulator of estrogen, progesterin, androgen, and glucocorticoid receptors in the central and peripheral tissues. *J Steroid Biochem.*, 34: 219–227.
- Katzer, G. (2004). *Nigella*: view the names of this plant in 48 languages Available at: http://www.uni-graz.at/~katzer/engl/Nige_sat.html Accessed March 8, 2007.
- Keating, N.L., Cleary, P.D., Rossi, A.S., Zaslavsky, A.M. and Ayanian, J.Z. (1999). Use of hormone replacement therapy by postmenopausal women in United States. *Ann Intern Med.*, 130:545-553.
- Keller, C., Fullerton, J. and Mobley, C. (1999). Supplemental and complementary alternatives to hormone replacement therapy. *Journal of the American Academy of Nurse Practitioners*, 11(5):187-198.
- Kelly, G.S. (2001). Conjugated linoleic acid: A review. *Altern Med Rev.*, 6:367–82.
- Keshri G, Singh MM, Lakshmi V. and Kamboj VP. (1995). Post-coital contraceptive effect of the seeds of *Nigella sativa* in rats. *Indian J Physiol Pharmacol.*, 39 (1): 59-62.
- Keshri, G., Lakshmi, V., and Singhe, M. M. (1998). Post-coital contraceptive activity of some indigenous plants in rats. *Contraception*, 57: 357-360.

- Kessel, B. (1998). Alternatives to estrogen for menopausal women. *Proceedings of the Society for Experimental Biology and Medicine*, 217: 38–44.
- Khare, C.P. (2003). *Indian Herbal Remedies: Rational western Therapy Ayurvedic and other*. Springer-Verlay, Berlin, Germany. pp. 330-331.
- Killen, J.H., Forrest, D.W., Byers, F.M., Schelling, G.T. and Long, C.R. (1989). Gonadotropin-releasing hormone-induced luteinizing hormone release in heifers: effect of nutrition during gestation. *Journal of Theoretical Biology*, 67: 496–500.
- Klahr, S., Buerkert, J. and Purkerson, M.L. (1983). Role of dietary factors in the progression of chronic renal disease. *Kidney International*, 24: 579-587.
- Kleijnen, J. (1994). Evening primrose oil: currently used in many conditions with little justification. *Br Med J.*, 309 (1): 824–825.
- Knight, DC. and Eden, JA. (1996). A review of the clinical effects of phytoestrogens. *Obstet Gynecol.*, 87:897-904.
- Kohama, S.G., Anderson, C.P., Osterburg, H.H., May, P.C. and Finch, C.E., (1989). Oral administration of estradiol in young C57BL/6J mice induces age-like neuroendocrine dysfunctions in the regulation of estrous cycles. *Biol. Reprod.*, 41; 227-232.
- Korenman, S.G. and Morely, J.E. (1992). *Endocrinology and metabolism in the elderly*. Boston: Blackwell Scientific publishers.
- Korenman, S.G., Sherman, B.M. and Korenman, J.C. (1978). Reproductive hormone function: The perimenopausal period and beyond. *Clinics in Endocrinology and Metabolism*, 7:625–643.
- Krajewski, S. J., Abel, T. W., Voytko, M. L., and Rance, N. E. (2003). Ovarian steroids differentially modulate the gene expression of gonadotropin-releasing hormone neuronal subtypes in the ovariectomized cynomolgus monkey. *J Clin Endocrinol Metab.*, 88, 655-662.
- Kronenberg, F. and Fugh-Berman, A. (2002). Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials, *Ann Intern Med.*, 137: 805–813.
- Kuiper, G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S. and Gustafsson, J.A. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor α and β . *Endocrinology*, 138: 863–870.

- Kuiper, G., Lemmen, J., Carlsson, B., Corton, J.C., Safe, S.H., van der Saag, P.T., Vander Burg, B. and Gustafsson, J.A. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. *Endocrinology*, 139 (10): 4252–4263.
- Kumagai, S., Kai, Y. and Sasaki, H. (2001). Relationship between insulin resistance, sex hormones and sex hormone-binding globulin in the serum lipid and lipoprotein profiles of Japanese postmenopausal women. *Journal of Atherosclerosis and Thrombosis*, 8:14–20.
- Kushwaha, R. S., Foster, D. M., Barrett, P. H. Carey, M. and Bernard, G. (1991). Metabolic regulation of plasma apolipoprotein E by estrogen and progesterone in the baboon (*Papio* sp). *Metabolism: Clinical and experimental*, 40(1); 93-100.
- Labhal, A., Settaf, A., Bennani-Kabchi, N., Cherrah, Y., Slaoui, A., Hassar, M. (1997). Action anti-obésité, hypocholestérolémiant et hypotriglycéridémiant de *Nigella sativa* chez le Psammomys obesus. *Caducée*, 27: 26-28.
- Labhal, A., Settaf, A., Zalagh, F., Cherrah, Y., Hassar, M., Slaoui, A. (1999). Propriétés anti-diabétiques des graines de *Nigella sativa* chez le Meriones shawi obese et diabétique. *Espérance Médicale*, 47: 72-74.
- Lambrinoudaki, I., Christodoulakos, G., Rizos, D., Economou, E., Argeitis, J., Vlachou, S., Creatsa, M., Kouskouni, E. and Botsis, D. (2006). Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. *European Journal of Endocrinology*, 154:907–916.
- Lark, S. (2002). Foods to Avoid or limit, excerpted from the woman's Health Companion 2002, healthy.net.
- Le, P.M., Benhaddou-Andaloussi, A., Settaf, A., Cherrah, Y. and Haddad, P.S. (2004). The petroleum ether extract of *Nigella sativa* exerts lipid lowering action in the rats. *J Ethanopharmacol.* 94(2-3): 251-9.
- Lee, K.N., Kritchevsky, D. and Pariza, M.W. (1994). Conjugated linoleic acid and atherosclerosis in rabbits. *Atherosclerosis*, 108:19–25.
- Lenton, E.A., Kretser, D.M., Woodward, A.J. and Robertson, D.M. (1991). Inhibin concentrations throughout the menstrual cycles of normal, infertile, and older women compared with those during spontaneous conception cycles. *J Clin Endocrinol Metab.*, 73(6), 1180-90.
- Leonetti, H.B., Longo, S. and Anasti, J.N. (1999). Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol.*, 94:225-228.

- Liberti, L. and Marderosian, A. (1978). Evaluation of commercial ginseng products. *J Pharm Sci.*,10 :1487–1489.
- Liehr, J.G. (2000). Is estradiol a genotoxic mutagenic carcinogen? *Endocrine Reviews*, 21; 40–54.
- Liu, M., Xu, X., Rang, W., Li, Y., and Song, Y. (2004). Influence of ovariectomy and 17 β -estradiol treatment on insulin sensitivity, lipid metabolism and post-ischemic cardiac function. *International journal of cardiology*,97(3): 485-493.
- Liu, J., Burdette, J.E., Xu, H., Gu, C., van Breemen, R.B., Bhat, K.P. (2001). Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. *J Agric Food Chem.* 49(5): 2472-2479.
- Lobo, R. (2000). Menopause management for the millennium. *Medscape Women's Health*. December 13, 2000.
- Long, J. A. and Evans, H. M. (1922). The estrous cycle in the rat and its associated phenomena. *Memories of University of California*, 6: 1-148.
- Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Mailliard, J.A., La Vasseur, B.L., Barton, D.L., Novotny, P.J., Dakhil, S.R., Rodger, K., Rummans, T.A. and Christensen, B.J . (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. *Lancet*,356: 5059-5063.
- Loprinzi, C.L., Sloan, J.A., Perez, E.A., Quella, S.K., Stella, P.J., Mialliard, J.A., Halyard, M.Y., Pruthi, S., Novotny, P.J. and Rummans, T.A. (2002). Phase III evaluation of floxetine for treatment of hot flashes. *J Clin Oncol.*,20: 1578-1583.
- Lu, K. H., Hopper, B. R., Vargo, T. M., and Yen, S. S. (1979). Chronological changes in sex steroid, gonadotropin, and prolactin secretion in ageing female rats displaying different reproductive states. *Biol Reprod.*,21, 193–203.
- Lu, J.H.K., Gilman, D.P., Meldrum, D.R., Judd, H.L. and Sawyer, C.H. (1981). Relationship between circulating estrogen and the central mechanisms by which ovarian steroids stimulate luteinizing hormone secretion in aged an young female rats. *Endocrinology*,108 (3); 836–841.
- Lubna, P. (2006). Progesterone: a "weight watcher's pill" for reproductively aging women. *Menopause*,13(2):166-167.
- Lupton, D. (1996). Constructing the menopausal body: the discourses on hormone replacement therapy, *Body Soc.*,2; 91–97.
- Mac Laren, A. and Woods, N.F. (2001). Midlife women making hormone therapy decisions. *Women Health Issues*,11(3), 216-230.

- MacLennan, A., Lester, S. and Moor, J. (2002). Oral estrogen replacement therapy versus placebo for hot flashes: a systematic review. *Climacteric*4:58-74.
- Mahady, G.B., Parrot, J., Lee, C., Yun, G.S. and Dan, A. (2003). Botanical dietary supplement use in peri- and postmenopausal women. *Menopause*,10:65–72.
- Mai Le, P., Benhaddou-Andaloussi, A., Elimadi, A., Settaf, A., Cherrah, Y. and Haddad, P.S. (2004). The petroleum ether extract of *Nigella sativa* exerts lipid-lowering and insulin-sensitizing actions in the rat. *Journal of Ethnopharmacology*, 94(2-3); 251-259.
- Manassiev, N. and Whitehead, M. I. (2003). Female Reproductive Health. New York : Parthenon Pub. Group, USA. pp:23-33.
- Mandle, A. M. (1951). The phases of the oestrous cycle in the adult white rat. *J. Exp. Biol.*, 28, 576-84.
- Manson, J.E, and Martin, K.A. (2001). Postmenopausal hormone-replacement therapy. *N Engl J Med.*, 345:34-40.
- Marcondes, F. K., Miguel, K., Melo, L. L. and Spadarisch-Bratfisch, R. C. (2001). Estrous cycle influences the response of female rats in the elevated plus-maze. *Physiol. Behav.*, 74(4-5): 435-440.
- Martin, L., Finn, C.A. and Trinder, G. (1973). Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autoradiographic study. *Journal of Endocrinology*,56:133–144.
- Matsuzaki Y., Kawaguchi E., Norita Y. (1996). Evaluation of Two Kinds of Reagents for Direct Determination of HDL-Cholesterol. *J. Anal Bio. Sci.*,19:419-427.
- Mc Gee, B. (2003). *Nigella Sativa*. Epicenter. Available at: <http://www.theepicentre.com/spices/nigella.html>. Accessed June 19, 2006.
- McKay Hart, D. and Norman, J. (2000). *Gynecology Illustrated*. 5th edition, London: Churchill Livingstone. pp. 412-413.
- Mc Kinlay, S.M., Brambilla, D.J. and Posner, J.G. (1992). The normal menopause transition. *Maturitas*,14(2), 103-115.
- McKenna, D., Jones, K., Humphrey, S. and Hughes, K. (2001). Black cohosh: efficacy, safety, and use in clinical and preclinical applications. *Altern Ther Health Med.*, 7 (3): 93–100.
- McManus, J.F.A. (1960). Staining methods. Harper and Row, New York.

- McNagny, S. (1999). Prescribing hormone replacement therapy for menopause symptoms. *Ann Intern Med.*,131:605-613.
- Meddah, B., Ducroc, R., Faouzi, M.E.A., Eto, B., Mahraoui, L., Benhaddou-Andaloussi, A., Martineau, L.Ch., Cherrah, Y. and Haddad, P.S. (2009). *Nigella sativa* inhibits intestinal glucose absorption and improves glucose tolerance in rats. *Journal of Ethnopharmacology*,121(3); 419-424.
- Melton, L.J. (1995). Epidemiology of fractures. Osteoporosis: Etiology, Diagnosis, and Management. Second Edition. In: Riggs, B.L., Melton, L.J., editors. Lippincott-Raven Publishers; Philadelphia: pp. 225–247.
- Mendenica, R., Mukerjee, S., Aloui, K., Mahassine, N., Amarouch, H. and Hassar, M. (1993). *Nigella Sativa* plant extract increases number and activity of immune compartment cells in humans. *J Experimental hematology*,21:1186-1189.
- Menotti, A. (1999). Diet, cholesterol and coronary heart disease. *A perspective*. *Acta Cardiologica*,54:169–172.
- Meral, I., Yener, Z., Kahraman, T. and Mert, N. (2001).Effect of *Nigella sativa* on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. *J Vet Med A.*,48: 593-599.
- Messinger, J.B. (2002). Prevention for the older woman: a practical guide to prevention and treatment of osteoporosis-continuing series, part 3. *Geriatrics*,57 (4);16–23.
- Million women study collaborators. (2003). Breast cancer and hormone replacement therapy in the million women study. *Lancet*. 362: 419-427.
- Mirzaiinjmaadi, K.M., Anderson, D. and Barnes, M. (2006). The relationship between exercise, body mass index and menopausal symptoms in midlife Australian women. *Int J Nurs Pract.*,12, 28-34.
- Moellenberg, D. R. (2003). Is it hot in here, or is it just ewe? Colorado State Research points to sheep as perfect model to study effect of menopause. *CSU in the News*, 970:491-6009.
- Mohd Zulkefli, N.A., and Mohd Sidik, S. (2003). Prevalence of menopausal symptoms among female teachers in Seremban, Negeri Sembilan: *Asia Pac Fam Med.*,2 (4): 235-7.
- Molitch, M.E. (1995). Neuroendocrinology. In: Felig, P., Baxter, J.D. and Frohman, L.A., eds. *Endocrinology and Metabolism*. New York: McGraw–Hill, Health Professions Division, pp. 221–288.

- Moya-Camarena, S.Y. and Belury, M.A. (1999a). Species differences in the metabolism and regulation of gene expression by conjugated linoleic acid. *Nutr Rev.*,57:336–40.
- Moya-Camarena, S.Y. and Belury, M.A. (1999b). CLAs and PPAR gamma activation. *J Nutr.*,129:602–6.
- Nagata, C., Nagao, Y., Shibuya, C., Kashiki, Y. and Shimizu, H. (2005). Fat intake is associated with serum estrogen and androgen concentrations in postmenopausal Japanese women. *Journal of Nutrition*,135:2862–2865.
- Najmi, A., Haque, Sh. F., Khan, R. A. and Nasiruddin, M. (2008). Therapeutic Effect Of *Nigella Sativa* Oil On Different Clinical And Biochemical Parameters In Metabolic Syndrome. *Int J Diabetes and Metabolism*,16: 85-87.
- Namkung-Matthai, H., Appleyard, R., Jansen, J., Hao Lin, J., Maastricht, S., Swain, M., Mason, R.S., Murrell, G.A.C., Diwan, A.D. and Diamond, T. (2001). Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. *Bone*,28(1):80-86.
- NAMS. (North American Menopause Society). (2004). Treatment of menopause-associated vasomotor symptoms: position statements of the North American menopause Society. *Menopause*, 11:11-33.
- NAMS. (North American Menopause Society). (2004).Recommendations for estrogen and progestogen use in peri- and postmenopausal women: *Menopause*,11:589-600.
- NAMS. (North American Menopause Society). (2007). Menopause Practice: A Clinician’s Guide. Section A: Overview of menopause and aging. Available at: www.menopause.org/edumaterials/studyguide/A.pdf. Accessed December 9, 2007.
- NAMS. (North American Menopause Society). (2007). Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. *Menopause*,14:168-82.
- NCCAM. (National Center for Complementary and Alternative Medicine). (2005). What is CAM? Available at: <http://nccam.nih.gov/health/whatiscam/>. Accessed July 13, 2006
- Nelson, H.D., Haney, E., Humphrey, L., Miller, J., Nedrow, A. and Nicolaidis, C. (2005). Management of Menopause-Related Symptoms. Evidence Report/Technology Assessment No. 120. AHRQ Publication No. 05-E016-2. Rockville, MD: Agency for Healthcare Research and Quality.

- Nelson, M. E., Rejeski, W.J., Blair, S.N., Duncan, P. W., Judge, J.O., King, A.C., Macera, C.A., and Carmen Castaneda-Sceppa, C. (2007). Physical Activity and Public Health in Older Adults: Recommendation from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc.*, 116:1094–1105.
- Nelson, H.D., Humphreg, L.L., Nygren, P., Tuetsch, S.M. and Allan, J.D. (2002). Postmenopausal hormone replacement: Scientific review. *JAMA.*, 288:872-881.
- Nergiz, C. and Otles, S. (1993). Chemical composition of *Nigella Sativa* L. Seeds. *J. Food Chemistry*, 48:259-261.
- Newcomb, P.A., Klein, R., Klein, B.E.K., Haffner, S., Mares-Perlman, J., Cruickshanks, K.J. and Marcus, P.M. (1995). Association of dietary and life-style factors with sex hormones in postmenopausal women. *Epidemiology*, 6:318-321.
- Nickavar, B., Mojab, F., Javidni, K., and Roodgar Amoli, M.A. (2003). Chemical Composition of the Fixed and Volatile Oils of *Nigella sativa* L. from Iran. *Z. Naturforsch*, 58c, 629-631.
- Nicolosi, R.J., Rogers, E.J. and Kritchevsky, D. (1997). Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. *Artery*, 22:266–77.
- Niwa, K., Morishita, S., Hashimoto, M., Itoh, T., Fujimoto, J., Mori, H. and Tamaya, T. (1998). Effects of tamoxifen on endometrial carcinogenesis in mice. *Japanese Journal of Cancer Research*, 89: 502–509.
- Norton, B. (1998). Black Seed: why it should be included in your daily diet? *Nature's Impact Magazine*, Available at: <http://www.kareandhope.com/articles/blackseedsecret.html>. Accessed December 25, 2007.
- Okazaki, K., Okazaki, S., Nakamura, H., Kitamura, Y., Hatayama, K., Wakabayashi, S., Tsuda, T., Katsumata, T., Nishikawa, A. and Hirose, M. (2002). A repeated 28-day oral dose toxicity study of genistein in rats, based on the 'Enhanced OECD test guideline 407' for screening endocrine-disrupting chemicals. *Archives of Toxicology*, 76: 553–559.
- Oropeza, M.V., Orozco, S., Ponce, H. and Campos, M.G. (2005). Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. *Reproductive Toxicology*, 20: 261–266.
- Overk, C.R., Booth, N.L., Yao, P., Burdette, J.E., Nikolic, D., Chen, S., Bolton, J.L., Breemen, R.B., Pauli, G.F., and Farnsworth, N.R. (2007). The Chemical and Biological Profile of a Red Clover (*Trifolium pratense*) Phase II Clinical Extract. *J Altern Complement Med.*, 12(2): 133–139.

- Page, R. and Lawrence, J.D. (1999). Potentiation of warfarin by dong quai. *Pharmacotherapy*, 19 (7):870–876.
- Pan, H.A., Wu, M.H., Hsu, C.C., Yao, B.L., Huang, K.E. (2002). The perception of menopause among women in Taiwan. *Maturitas*, 41:269–74.
- Pandya, K.J., Raubertas, R.F., Flynn, P.J., Hynes, H.E., Rosenbluth, R.J., Kirshner, J.J., Pierce, H.I., Dragaline, V. and Morrow, G.R. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifene-induced hot flashes: a university of Rochester cancer center community clinical oncology program study. *Ann Intern Med.*, 132: 788-793.
- Parodi, P.W. (1999). Conjugated linoleic acid and other anticarcinogenic agents of bovine milk fat. *J Dairy Sci.*, 82:1339–49.
- Pasquali, R., Vicennati, V., Bertazzo, D., Casimirri, F., Pascal, G., Tortelli, O. and Morselli Labate A. M. (1997). Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. *Metabolism.*, 46: 5-9.
- Peck, L.W., Nickel, K.P. and Belury, M.A. (1998). Dietary conjugated linoleic acid normalizes impaired glucose tolerance in Zucker diabetic fatty fa/fa rat. *Biochem Biophys Res Commun*, 244:678–82.
- Pepping, J. (1999). Black cohosh: *Cimicifuga racemosa*. *Alternative Therapies. American Journal of Health-System Pharmacy*, 56(14):1400-1402.
- Perry, C. and Berliner, S. (1998). Progesterone and the risk of arterial and venous thrombosis. *Harefuah*, 134: 633-7.
- Persson, I., Bergkvist, L., Lindgren, C. and Yuen, J. (1997). Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. *J Clin Epidemiol.*, 50:611-8.
- Persson, I. (1989). Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestones: results of a prospective study. *BMJ.*, 298:147 - 151.
- Petitti, D. (2003). Hormone replacement therapy and coronary heart disease: results of randomized trials. *Progress in Cardiovascular Diseases*, 46(3). 231-238.
- Prakash, A.O. and Mathur, R., (1979). Biochemical changes in the rat uterine tissue following *Embelia ribes* extracts. *Indian Journal of Pharmacology*, 11,127–134.

- Prentice, R.L., Caan, B., Chlebowski, R.T., Patterson, R., Kuller, L.H., Ockene, J.K., Margolis, K.L., Limacher, M.C., Manson, J.E., Parker, L.M., Paskett, E., Phillips, L., Robbins, J., Rossouw, J.E., Sarto, G.E., Shikany, J.M., Stefanick, M.L., Thomson, C.A., Van Horn, L., Vitolins, M.Z., Wactawski-Wende, J., Wallace, R.B., Wassertheil-Smoller, S., Whitlock, E., Yano, K., Adams-Campbell, L., Anderson, G.L., Assaf, A.R., Beresford, S.A. and Black, H.R. (2006). Low fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomised Controlled Dietary Modification Trial. *JAMA.*, 295:629-642.
- Progetto Menopausa Italia Study Group. (2005). Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy. *Maturitas*, 52, 181-189.
- Qidwai, W., Hamza, H.B., Qureshi, R. and Gilani, A. (2009). Effectiveness, Safety, and Tolerability of Powdered *Nigella sativa* (*Kalonji*) Seed in Capsules on Serum Lipid Levels, Blood Sugar, Blood Pressure, and Body Weight in Adults: Results of a Randomized, Double-Blind Controlled Trial. *The Journal of Alternative and Complementary Medicine*, 15(6): 639-644.
- Rajion, M.A., Goh, Y.M., Dahlan, I. and Salam Abdullah, A. (2000). Dietary Manipulation and increase in plasma unsaturated Fatty Acids in sheep. *Asian-Australian Journal of Animal Sciences*, 14(8):1073-1077.
- Rapp, S.R., Espeland, M.A., Shumaker, S.A., Henderson, V.W., Brunner, R.L., Manson, J.E., Gass, M.L.S., Stefanick, M.L., Lane, D.S., Hays, G., Johnson, K.C., Coker, L.H., Daitey, M. and Bo Wen, D. (2003). Effect of estrogen plus progestin on global cognitive function in post menopausal women: The women's Health Initiative memory study: a randomized controlled trial. *JAMA.*, 289:2663-2672.
- Raz, R. and Stamm, W.E.A. (1993). Controlled trial of intravaginal esteriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med.*, 329:753-756.
- Randhawa, T. and Al-Ghamdi, M.S. (2002). A review of the pharmacotherapeutic effects of *Nigella sativa*. *Pakistan Journal of Medical Research*, 41:77-83.
- Riad, R. M., Ghoniem, A. A. M. and Seleem, T. S. T. (2004). Effect of *Nigella sativa* (aquas extract) on the viability of rabbit spermatozoa, fertility traits and bacterial contamination. *Assiut Veterinary Medical Journal*, 50(103):199-211.
- Riedel, M.J., Boora, P., Steckley, D., deVries, G. and Light, P.E. (2003). Polymorphisms sensitize B-cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes. *Diabetes*, 52: 2630-2635.

- Rifai, N., Warnick, G.R., McNamara, J.R., Belcher, J.D., Grinstead, G.F. and Frantz, J. I.D. (1992). Measurement of Low-Density Lipoprotein Cholesterol in Serum: a Status Report. *Clin. Chem.*, 38:150-160.
- Riggs, B.L. and Hartmann, L.C. (2003). Selective estrogen- receptor modulators- mechanisms of action and application to clinical practice. *N Engl J Med.*, 348: 618-629.
- Rimoldi, G., Christoffel, J., Wuttke, D. S., Jarry, H. and Wuttke, W. (2007). Effects of Chronic Genistein Treatment in Mammary Gland, Uterus, and Vagina. *Environmental Health Perspectives*, 115(S1): 62-68.
- Riserus, U., Berglund, L. and Vessby, B. (2001). Conjugated linoleic acid (CLAs) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial. *Int J Obes Relat Metab Disord.*, 25:1129–35.
- Riserus, U., Arner, P. and Brismar, K. (2002). Treatment with dietary trans10 cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. *Diabetes Care*, 25:1516–21.
- Rodgers, J.B., Monierfaugere, M.C. and Malluche, H. (1973). Animal models for the study of bone loss after cessation of ovarian function. *Bone*, 14:369–377.
- Roemheld-Hamm, B. (2005). Chasteberry. *American Family Physician*, 72(5):821-4.
- Roghani Dehkordi, F. and Kamkhah, A.F. (2008). Antihypertensive effect of *Nigella sativa* seed extract in patients with mild hypertension. *Fundamental and clinical Pharmacology*, 22(4):447-453.
- Ronda, S.R. and Lele, S.S. (2008). Culture Conditions stimulating high γ -Linolenic Acid accumulation by *Spirulina platensis*. *Braz. J. Microbiol.*, 39(4); 693-697.
- Ross R. (1999). Atherosclerosis: an inflammatory disease. *N Engl J Med.* 340:115-126.
- Rossi, R., Grimaldi, T., Origliani, G., Fantini, G., Coppi, F. And Modena, M.G. (2002). Menopause and cardiovascular risk. *Pathophysiol Haemost Thromb.*, 32:325-328.
- Rossouw, J.E., Anderson, G.L., Prentico, R.L., Lacroix, A.Z., Kooperberg, C., Hutchinson, F., Stefanick, M.L., Jackson, R.D., Beresford, S.A.A., Howard, B.V., Johnson, K.C., Kotchen, J.M. and Ockene, J. Writing group for the women's Health Initiative Investigators. (2002). Risks and benefits of estrogen

plus progestin in healthy postmenopausal women. Principle results from the women health initiative randomized controlled trial. *JAMA.*, 288:321-333.

Rudel, L.L. (1999). Atherosclerosis and conjugated linoleic acid. *Br J Nutr.* 81:177–9.

Ruentiz, P.C. (2003). Female sex hormones, contraceptives and fertility drugs. In Abraham, D.J. (Ed.), *Burger's Medicinal Chemistry and Drug Discovery*, vol. 3. John Wiley and Sons Inc. USA. pp. 629-660 (Chapter 13).

Sabrina, S. (2008). Breeding in laboratory animals. Lecture Materials. (Course code: BMS 3140). Personal Communication.

Saleh , C., El-saleh, Othman, A., Al-sagair, M. and Al-khalaf. I. (2004). Thymoquinone and *Nigella Sativa* oil protection against methionine-induced hyperhomocysteinemia in rats. *Int J Cardiol.*, 93(1):19-23.

Saleh Mansi, K.M. (2005). Effect of oral administration of water extract of *Nigella sativa* on serum concentrations of Insulin and Testosterone in alloxan induced diabetic rats. *Pakistan Journal of Biological Sciences*, 8(8):1152-1156.

Salem, M. A. (2001). Effect of some heat treatment on *Nigella* seeds characteristics. 1- Some physical and chemical properties of *Nigella* seed oil. *J. Agric. Res. Tanta Univ.*, 27, 471–486.

Samaras, K., Kelly, P.J., Spector, T.D., Chiano, M.N. and Campbell, L.V. (1998). Tobacco smoking and oestrogen replacement are associated with lower total and central fat in monozygotic twins. *Int J Obes Relat Metab Disord.*, 22: 149 - 156.

Samuelsson, B., Granström, E., Green, K. and Hamberg, M. (1972). Metabolism of prostaglandin. *Ann NY Acad Sci.*, 180:138–163.

Santoro, N., Brown, J.R., Adel, T. and Skurnick, J.H. (1996). Characterization of reproductive hormonal dynamics in the premenopause. *J Clin Endocrinol Metab.*, 81(4), 1495-501.

Sathanandan, S.M. and Jacobs, H.S. (2002). *Practical Guide to Ovulation Induction*. Imperial College Press. UK.

Schaper, G. and Brummer, H.(1997). The herbal preparation for gynecology: *scientific brochure*. Schaper and Brummer, Salzgitter, Germany.

Schleicher, P. (2005). Black Seed, the magical herb. Shifa 2005 Available at: http://www.shifalife.com/etrading/black_seed Accessed April16, 2007.

- Scholten, A. (2009). Reducing Your Risk of Complications Associated With Menopause. Available at: <http://www.thirdage.com/encyclopedia/reducing-your-risk-of-complications-associated-with-menopause>. Accessed February 14, 2009.
- Scholten, A. (2003). Life style changes to manage menopause. Available at: <http://www.thirdage.com/menopause/hormone-replacement-therapy-hrt-does-it-reduce-heart-disease-risk-in-postmenopausal-women-0> Accessed September 9, 2008.
- Schwartzmann, G. , Ratain, M.J., Cragg, G.M. , Wong, J.E., Saijo, N., Parkinson, D.R., Fujiwara, Y., Pazdur, R., Newman, D.J., Dagher, R. and Di Leone, L. (2002). Anticancer Drug Discovery and Development throughout the World. *Journal of Clinical Oncology*,20(18S): 47s-59s.
- Schwartz, N. B. (1964). Acute effects of ovariectomy on pituitary LH, uterine weight, and vaginal cornification. *Am. J. Physiol.*, 107: 1251-1259.
- Schwartz-Bloom, R.D. and Halpin, M. (2003). Steroids and athletes: Genes work overtime. Pharmacology Education Partnership. Available at: www.thepeproject.net. Accessed May 29, 2009.
- Scully, R.E., Bonfiglio, T.A., Kurman, R.J., Silverberg, S.G. and Wilkinson, E.J. (1994). Histological Typing of Female Genital Tract Tumours (International Histological Classification of Tumours), 2:13–18. Geneva:WHO.
- Seeman, E. (2002). Pathogenesis of bone fragility in women and men. *Lancet*,359:1841-1850.
- Setchell, K.D. and Cassidy, A. (1999). Dietary isoflavones: biological effects and relevance to human health. *J. Nutr.*, 129; 758s-767s.
- Setchel, K.D.R., Brown, N.M., Desai, P.B., Zimmer-Nechimas, L., Wolfe, B.E., Brashear, W.T., Kirschner, A.S., Cassidy, A. and Heubi, J.E. (2001). Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplement. *J Nutr.*, 131:1362s-1375s.
- Settaf, A., Berrada, Y., Haddad, P.S., Cherrah, Y., Hassar, M. and Slaoui, A. (2000). Volatile oil of *Nigella sativa* lowers plasma lipids and insulin in obese hyperlipidemic sand rats (*Psammomys obesus*), 6th International Congress on Ethnopharmacology: P2A/36.
- Sharafkhandy, A. (1990). *Avicenna's Law in Medicine* [Qanon]. Tehran: Ministry of Guidance Publication.
- Shelley, J.M., Green, A., Smith, A.M., Dudley, E., Dennerstein, L., Hopper, J. and Burger, H. (1998). Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. *Annals of Epidemiology*, 8:39–45.

- Shepherd, J., Packard, C.J., Grundy, S.M., Yeshurun, D., Gotto J. A.M. and Taunton, O.D. (1980). Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. *Journal of Lipid Research*, 21:91-99.
- Sherman, Sh., Miller, H., Nerurkar, L., Schiff, I. (2005). Research opportunities for reducing the burden of menopause-related symptoms. *The American Journal of Medicine*, 118 (12B):166S–171S.
- Shukla, S., Mathur, R. and Prakash, A.O. (1987). Effect of butanolic extract of *Peraria tuberosa* DC. on the oestrous cycle of adult rats. *Indian Journal of Pharmacology*, 19: 49–53.
- Shumaker, S.A., Legault, C., and Kuller, L., (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. *JAMA.*; 291:2947–2958.
- Shumaker, S.A., Legault, C. and Rapp, S.R. (2003). Estrogen plus progestin and the incidence and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA.*, 289:2651-62.
- Siedel, J. (1993). AACC Meeting Abstract 34. *Clin Chem.*, 39:1127.
- Silberstein, S. D. and Merriam, G. R. (2000). Physiology of the menstrual cycle. *Cephalalgia*, 20, 148-154.
- Silverberg, S.G. (2000). Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. *Modern Pathology*, 13: 309–327.
- Simonic, V., Banović, I., Ciglar, S., Jeren, L., Baldani, D.P. and Šperm, M. (2003). Local estrogen treatment in patient with urogenital symptoms. *Int J Gynecol Obstet.*, 82:187-197.
- Simpkins, J.W. and Van Meter, R.(2005). Potential Testosterone Therapy for Hypogonadal Sexual Dysfunction in Women. *Journal of Women's Health*. 14(5): 449-451.
- Simpson, E.R. (2003). Sources of estrogen and their importance. *Journal of Steroid Biochemistry and Molecular Biology*, 86:225–230.
- Siiteri, P.K. (1987). Adipose tissue as a source of hormones. *American Journal of Clinical Nutrition*, 45:277–282.
- Sites, C.K., Toth, M.J., Cushman, M., L’Hommediev, G.D., Tchernof, A., Tracy, R.P. and Poehlman, E.T. (2002). Menopause-related differences in inflammation

markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. *Fertile Sterile.*, 77:128-135.

- Sites, C.K., Georgia, C.K., L'Hommedieu, D., Michael J. Toth, M. J., Brian, B., Cooper, C. and Fairhurst, P. A. (2005). The Effect of Hormone Replacement Therapy on Body Composition, Body Fat Distribution, and Insulin Sensitivity in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial. *Journal of Clinical Endocrinology & Metabolism*,90 (5):2701-2707.
- Slaven, L., and Lee, C. (1997). Mood and Symptom Reporting Among Middle-Aged Women: The Relationship between Menopausal Status, Hormone Replacement Therapy, and Exercise Participation. *Health Psychology*,16: 203-208.
- Smedman, A. and Vessby, B. (2001). Conjugated linoleic acid supplementation in humans metabolic effects. *Lipids*, 36:773-8.
- Smith, M. S., Freeman, M. E., and Neill, J. D. (1975). The control of progesterone secretion during the estrous cycle and early pseudo pregnancy in the rat: Prolactin, gonadotropin and steroid levels associated with rescue of corpus luteum of pseudopregnancy. *Endocrinology*,96, 219-26.
- Smith, K.E. and Judd, H.L. (1994). Menopause and post menopause in Decherney AH, Pernoll ML. *Current Obstetric and Gynecologic Diagnosis and treatment*. 8th ed Appelton and Lange. pp.1030-1050.
- Smith, N.L., Heckbert, S.R. and Lemaitre, R.N. (2004). Esterified estrogens and conjugated equine estrogens and the risk for venous thrombosis. *JAMA.*, 292:1581-7.
- Smolinski, D., Wolliner, D., Orłowski, J., Curcio, J., Nevels, J. and Kim, L. (2005). Evaluate Herbal Combination for Menopausal Symptoms, A pilot study to examine a combination botanical for the treatment of menopausal symptoms. *J Altern Complement Med.*,11(3): 473-489.
- Sohn, E., Daggy, B.P. and Arjmandi, B.H. (1999). Ovariectomized hamster:: A potential model of postmenopausal hypercholesterolemia. *The Journal of Nutritional Biochemistry*,10 (11);660-663.
- Spornitz, U. M., Socin, C. D. and David, A. A. (1999). Estrous stage determination in rats by means of scanning electron microscopic images of uterine surface epithelium. *The Anat. Rec.*,254: 116-126.
- Stadberg, E., Mattson, L.A. and Milson, I. (1997). The prevalence and severity of climactic symptoms and the use of different treatment regimens in a Swedish population. *Acta Obstet Gynecol Scand.*,76:442-448.

- Stampfer, M.J., Kang, J.H. and Chen, J. (2005). Effects of moderate alcohol consumption on cognitive function in women. *N Engl J Med.*, 352:245-253.
- Stangl, G.I. (2000). High dietary levels of conjugated linoleic acid mixture alter hepatic glycerophospholipid CLASS profile and cholesterol-carrying serum lipoproteins of rats. *J Nutr Biochem.*, 11:184–91.
- Staples, Ch. R. and Thatcher, W.W. (1999). Fat supplementation may improve fertility of lactating dairy cows. Proceedings of the Southeast Dairy Herd Management Conference. Macon, GA. 56.
- Stapleton, J. (2008). Breast cancer fall mirrors HRT decline. *The Australian, Online Newspaper of the Year.* June 02, 2008.
- Stearns, V., Ullmer, L., Lopez, J.F., Smith, Y., Isaacs, C. and Hayes, D.F. (2002). Hot flashes. *Lancet*, 360:1851-1861.
- Stephenson, J. (2003). FDA orders estrogen safety warnings: agency offers guidance for HRT use. *JAMA*, 289:537-538.
- Stevenson, J.C., Crook, D. and Godslan, I.F. (1993). Influence of age and menopause on serum lipids and lipoproteins in healthy women. *Atherosclerosis*,98:83-90.
- Stoll, B.A. (2002). Linkage between retinoid and fatty acid receptors: Implications for breast cancer prevention. *Eur J Cancer Prev.*,11: 319–325.
- STRAW (2001). Executive Summary: Stages of Reproductive Aging Workshop (STRAW) Park City Utah, July 2001, *Menopause*,8:402– 407.
- Stroheker, T., Chagnon, M. C., Pinnert, M. F., Berges, R. and Canivenc-Lavier, M.C. (2003). Estrogenic effects of food wrap packaging xenoestrogens and flavonoids in female Wistar rats: a comparative study. *Reproductive Toxicology*,17: 421–432.
- Sugiuchi, H., Uji, Y., Okabe, H. and Irie, T. (1995). Direct Measurement of High-Density Lipoprotein Cholesterol in Serum with Polyethylene Glycol-Modified Enzyme and Sulfated α -Cyclodextrin. *Clin. Chem.*, 41: 717-723.
- Sullivan, J.M. and Newman K. P. (1996). Coronary Heart Disease in Women: Epidemiology, Clinical Syndrome and Management . *Menopause*,3(1); 51-59.
- Suzuki, K.M. Isohama, Y., Maruyama, H., Yamada, Y., Narita, Y., Ohta, S., Araki, Y., Miyata, T. and Mishima, S. (2008). Estrogenic activities of Fatty acids and a sterol isolated from royal jelly. *Evid Based Complement Alternat Med.*, 5(3):295-302.

- Svendsen, O.L., Hassager, C. and Christiansen, C. (1993). Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. *Am J Med.*, 95:131-140.
- Swamy, S.H., and Tan, B.K. (2000) Cytotoxic and immuno-potentiating effects of ethanolic extract of *Nigella Sativa* seeds. *J.Ethenopharmacol.*, 70: 1-7.
- Takada, R., Saitoh, M. and Mori, T. (1994). Dietary gamma-linolenic acid-enriched oil reduces body fat content and induces liver enzyme activities relating to fatty acid beta- oxidation in rats. *J. Nutr.*, 124(4):496-74.
- Talavera, F., Park, C.S. and Williams, G.L. (1985). Relationships among dietary lipid intake, serum cholesterol and ovarian function in Holstein heifers. *Journal of Animal Science*, 60: 1045–1051.
- Tansey, G., Hughes, C. L., Jr, Cline, J. M., Krummer, A., Walmer, D. K. and Schmoltzer, S. (1998). Effects of dietary soybean estrogens on the reproductive tract in female rats. *Proc. Soc. Exp. Biol. Med.*, 217:340-344.
- Taylor, M. (2001). Nonhormonal alternatives for the menopause syndrome, *Infertility and Reproductive Medicine Chinese of North America*, 12(1), 669-685.
- Tchernof, A. and Poehlman, E.T. (1998). Effects of the menopause transition on body fatness and body fat distribution. *Obes Res.*, 6: 246 - 254.
- Teoman, N., Ozcan, A. and Acar, B. (2004). The effect of exercise on physical fitness and quality of life in postmenopausal women. *Maturitas*, 47(1); 71-77.
- Terenius, L. (1971). The Allen-Doisy test for estrogens reinvestigated. *Steroids*. 17,653-661.
- Thomas, L. (1998). *Labor und Diagnose*, 5th ed. Marburg::Die Medizinische Verlagsgesellschaft. Elsevier Churchill Livingstone. Philadelphia, USA.
- Thompson, D.D., Simmons, H.A., Pirie, C.M. and Ke, H.Z. (1995). FDA guidelines and animal models for osteoporosis. *Bone.*, 17 (4), Supplement 1:S125-S133.
- Thorndike, E.A. and Turner, A.S. (1998). In search of an animal model for postmenopausal diseases. *Front Biosci.*, 3:17–26.
- Tice, J.A., Ettinger, B., Ensrud, K., Wallace, R., Blackwell, T. and Cummings, S.R. (2003). Phytoestrogen supplements for the treatment of hot flashes – the Isoflavone Clover Extract (ICE) Study—a randomized controlled trial. *JAMA.*, 290:207–214.

- Tissera, MHA., Kumaranayaka, KS. and Serasinghe, P. (1997). Effect reduction of serum cholesterol by oil of *Nigella Sativa*. Baraka (Available at: <http://www.barakaoil.com/>)
- Toth, M. J., Tchernof, A., Sites, C. K. and Poehlman, E. T. (2000). Effect of menopausal status on body composition and abdominal fat distribution. *International Journal of Obesity*, 24: 226–231
- Treloar, A.E. (1981). Menstrual cyclicity and the pre-menopause. *Maturitas* 3:249-264.
- Tsai, H.W. and Legan, S.G. (2001). Chronic elevation of estradiol in ovariectomized rats causes aging-like loss of steroid-induced luteinizing-hormone surge. *Biol. Reprod.*, 64; 684-688.
- Tsai, H.W. and Legan, S.G. (2002). Loss of luteinizing-hormone surge induced by chronic estradiol is associated with decreased activation of gonadotropine releasing hormone neurons. *Biol. Reprod.*, 66; 1104-1110.
- Turkdogan, M.K., Agaoglu, Z., Yener, Z., Sekeroglu, R., Akkan, H.A. and Avci, M.E. (2001). The role of antioxidant vitamins (C and E), selenium and *Nigella sativa* in the prevention of liver fibrosis and cirrhosis in rabbits: new hopes. *Dtsch Tierarztl Wochenschr*, 108: 71-73.
- Turner, R.T., Vandersteenhoven, J.J. and Bell, N.H. (1987). The effects of ovariectomy and 12- α -estradiol on cortical bone histomorphometry in growing rats. *J Bone Miner Res.*, 2:115–122.
- Ukkola, O. (2003). Ghrelin and insulin metabolism. *Eur J Clin Invest.*, 33:183-185.
- Umland, E.M. (2008). Treatment Strategies for Reducing the Burden of Menopause Associated Vasomotor Symptoms. *JMCP.*, (Supplement). 14(3):S15- S19.
- Utian, W. H. (2004). Menopause-related definitions. *International Congress Series (ICS Elsevier)* 1266 (2004): 133– 138.
- Vaddadi, K. S. and Horrobin, D. F. (1979) Weight loss produced by evening primrose oil administration in normal and schizophrenic individuals. *IRCS Med. Sci.*, 7: 52.
- Vallette, G., Vanet, A., Sumida, C., Nunez, E.A. (1991). Modulatory effects of unsaturated fatty acids on the binding of glucocorticoids to rat liver glucocorticoid receptors. *Endocrinology*, 129: 1363–1369.
- Vandenakker, B.C. and Glass, D.D. (2002). Menopause and aging with disability. *Phys. Med. Rehabil. Clin. North Am.*, 12 (1):133–151.

- Van de Weijer, P.H.M. and Barentsen, R. (2002). Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. *Maturitas*, 42: 187–193.
- Van Linden, J.C., Waarsing, J.H. and Weinans, H. (2006). The use of micro-CT to study bone architecture dynamics noninvasively. *Drug Discovery Today: Technologies*, 3(2):213-219.
- Vance, D., Wadley, V., Ball, K., Roenker, D., and Rizzo, M. (2005). The effects of physical activity and sedentary behavior on cognitive health in older adults. *J Aging Phys Act.*, 13, 294-313.
- Vander Schouw, Y.T., Graaf Van der, Y., Steyerberg, E.W., Eijkemans, M.J.C. and Banga, J.D. (1996). Age at menopause as a risk factor for cardiovascular mortality. *Lancet*, 347:714-718.
- Vardy, M.D., Lindsay, R., Scotti, R.J., Mikhail, M., Richart, R.M., Nieves, J., Zion, M. and Cosman, F. (2003). Short term urogenital effects of raloxifene, tamoxifen, and estrogen. *AMJ Obstet Gynecol.*, 189:81-83.
- Vercellini, P., Vendola, N., Colombo, A., Passadore, C., Trespida, L. and Crosignani, P.G. (1992). Veralipride for hot flashes during gonadotropin-releasing hormone agonist treatment. *Gynaecol Obstet Invest.*, 34: 102-104.
- Vihan, V.S. and Panwar, H.S. (1987). Protective effect of *Nigella sativa* seeds on CCl₄-induced hepatotoxicity. *Indian Vet J.*, 64: 347-49.
- Walsh, J.M.E., Charney, P. and Nattinger, A. (1998). Update in women's health. *Ann Intern Med.*, 129:551-8.
- Walsh, B.W., Schiff, I., Rosner, B., Greenberg, L., Ravnkar, V. and Sacks, F.M. (1991). Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. *N. Engl. J. Med.*, 325; 1196–1204.
- Wang, X.J., Dyson, M.T., Jo, Y., Eubank, D.W. and Stocco, D.M. (2003). Involvement of 5-lipoxygenase metabolites of arachidonic acid in cyclic AMP-stimulated steroidogenesis and steroidogenic acute regulatory protein gene expression. *J Steroid Biochem Mol Biol.*, 85:159-166.
- Welberg, L.A.M., Kinkead, B., Thirvikraman, K.V., Huerkamp, M.J., Nemeroff, C.B. and Plotsky, P.M. (2006). Ketamine-xylazine-acepromazine anesthesia and postoperative recovery in rats. *J Am Assoc Lab Anim Sci.*, 45(2):13-20.
- Wells, G., Tuqwell, P., Shea, B., Peterson, J., Zytaruk, N., Robinson, V., Henry, D., O'connell, D. and Cranney, A. (2002). The Osteoporosis Methodology Group and the Osteoporosis Research advisory Group. Meta-analysis of the efficacy of

hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev.*, 23: 529-536.

Westwood, F.R. (2008). The Female Rat Reproductive Cycle: A Practical Histological Guide to Staging. *Toxicologic Pathology*, 36: 375-384.

Whitten, P.L., Russell, E. and Naftolin, F. (1992). Effects of a normal, human concentration, phytoestrogen diet on rat uterine growth. *Steroids*, 57:98–106.

Whitten, P.L., Russell, E. and Naftolin, F. (1994). Influence of phytoestrogen diets on estradiol action in the rat uterus. *Steroids*, 59:443–9.

Whyte, J. J., Alexenko, A. P., Davis, A. M., Ellersieck, M. R., Fountain, E. D. and Rosenfeld, C. S. (2007). Maternal diet composition alters serum steroid and free fatty acid concentrations and vaginal pH in mice. *Journal of Endocrinology*, 192:75–81.

Wierman, M. E. (2007). Sex steroid effects at target tissues: mechanisms of action. *Advan. Physiol. Edu.* 31: 26-33.

Williamson, E.M. and Okpako, D.T., (1996). Endocrine activity: antifertility and sex hormones. In: Evans, F.J. (Ed.), *Pharmacological Methods in Phytotherapy Research Selection. Preparation and Pharmacological Evaluation of Plant Material*, vol. 1. John Wiley and Sons, New York, pp. 191–216 (Chapter 11).

Williamson, J., White, A., Hat, A. and Ernest, E. (2002). Randomized controlled trial of reflexology of menopausal symptoms. *Br J Obstet Gynaecol.*, 109,1050-1055.

Wilson, P.W.F., Garrison, R.J., Castelli, W.P. (1985). Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. *N Engl J Med.*, 313:1038 - 1043.

Wilson, T.A., Nicolosi, R.J. and Chrysam, M, (2000). Conjugated linoleic acid reduces early aortic atherosclerosis greater than linoleic acid in hypercholesterolemic hamsters. *Nutr Res*, 20:1795–805.

Wixon, S.K. and Smiler, K.L. (1997). Anesthesia and Analgesia in Rodents, Chapter 9 in *Anesthesia and Analgesia in Laboratory Animals*, Kohn, D.J., Wixon, S.K., White, W.J., Benson, G.J. Eds., Academic Press.

Woods, M.N., Barnett, J.B., Spiegelman, D., Trail, N., Hertzmark, E., Longcope, C. and Gorbach, S.L. (1996). Hormone levels during dietary changes in premenopausal African–American women. *Journal of the National Cancer Institute*, 88:1369–1374.

- World Health Organization. (1996). Research on the Menopause in the 90s. Technical Report Ser 866, Geneva, Switzerland, World Health Organization.
- Worthen D.R., Ghosheh O.A. and Crooks P.A. (1998). The in vitro anti-tumor activity of some crude and purified components of black seeds, *Nigella sativa*. *Anticancer Res.*, 18: 1527-1532.
- Writing group for the Women's Health Initiative (WHI) Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy, postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.*, 288:321-333.
- Wuttke, W., Jarry, H., Becker, T., Schultens, A., Christoffel, V., Gorkow, C. and Seidlova-Wuttke, D. (2003). Phytoestrogens: endocrine disruptors or replacement for hormone replacement therapy? *Maturitas*, 44: S9– S20.
- Wynn, A. and Wynn, M. (1993). The effects of food shortage on human reproduction. *Nutrition and Health*, 9:43–52.
- Yaffe, K., Sawaya, G., Lieberburg, I. and Grady, D. (1998). Estrogen therapy in postmenopausal women: Effect on cognitive function and dementia. *JAMA.*, 279:688-695.
- Ylikorkala, O. (2003). HRT as secondary prevention of cardiovascular disease. *Maturitas* . 47: 315-318.
- Ylikorkala, O. and Metsa-Heikkila, M. (2002). Hormona replacement therapy in women with a history of breast cancer. *Gynaecol Endocrinol.*, 16:469-478.
- Young, W. C., Boling, J. L. and Blandau, R. (1941). The vaginal smear picture, sexual receptivity and time of ovulation in the albino rat. *Anat. Rec.*, 80: 37-45.
- Younus, J., simpson, I., Collins, A. and Wang, X. (2003). Mind control of menopause. *Women's Health issues*, 13, 74-78.
- Zandi, P.R., Carlson, M.C., Plassman, B.L., Welsh-bohmer, K.A., Mayer, L.S., Steffens, D.C. and Breitner, J.C.S. (2002). Hormone replacement therapy and incidence of Alzheimer disease in older women. The cache county study. *JAMA.*, 288:2123-2129.
- Zaoui, A., Cherrah, Y., Lacaille-Dubois, M.A., Settaf, A., Amarouch, H. and Hassar, M. (2000). Diuretic and hypotensive effects of *Nigella sativa* in the spontaneously hypertensive rat. *Therapie*, 55: 379-382.
- Zaoui, A., Cherrah, Y., Mahassini, N., Alaoui, K., Amarouch, H. and Hassar, M. (2002). Acute and chronic toxicity of *Nigella sativa* fixed oil. *Phytomedicin*, 9: 69–74.

Zhou, Y., Lin, S., Chang, H.H., Du, J., Dong, Z., Dorrance, A.M., Brands, M.W. and Wang, M.H. (2005). Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. *American Journal of Hypertension*, 18:530–537.

Zhu, D. (1987). Dong quai. *Am J Chin Med.*, 15:117–125.

Zunin, I. and Bregman, B. (2002). Menopause: conventional and complementary alternatives to hormone replacement therapy. *Integrative Med. Consult*, 4:126–127.

